Gene expression in the kidney of rats affected by metabolic syndrome: A meta-analysis by Hatchett, Brittany Leigh
James Madison University
JMU Scholarly Commons
Senior Honors Projects, 2010-current Honors College
Spring 2014
Gene expression in the kidney of rats affected by
metabolic syndrome: A meta-analysis
Brittany Leigh Hatchett
James Madison University
Follow this and additional works at: https://commons.lib.jmu.edu/honors201019
This Thesis is brought to you for free and open access by the Honors College at JMU Scholarly Commons. It has been accepted for inclusion in Senior
Honors Projects, 2010-current by an authorized administrator of JMU Scholarly Commons. For more information, please contact
dc_admin@jmu.edu.
Recommended Citation
Hatchett, Brittany Leigh, "Gene expression in the kidney of rats affected by metabolic syndrome: A meta-analysis" (2014). Senior
Honors Projects, 2010-current. 424.
https://commons.lib.jmu.edu/honors201019/424
Gene Expression in the Kidney of Rats Affected by Metabolic Syndrome: A Meta-Analysis 
_______________________ 
 
A Project Presented to 
 
the Faculty of the Undergraduate 
 
College of Science and Mathematics 
 
James Madison University 
_______________________ 
 
in Partial Fulfillment of the Requirements 
 
for the Degree of Bachelor of Science 
_______________________ 
 






Accepted by the faculty of the Department of Biology, James Madison University, in partial fulfillment of the 





       
Project Advisor:  Terrie Rife, Ph.D., 
Associate Professor, Biology 
 
 
       
Reader:  Janet Daniel, Ph. D., 
Associate Professor, Biology 
 
 
       
Reader:  Timothy Bloss, Ph.D., 
Associate Professor, Biology 
 
 
       
Reader:  Nusrat Jahan, Ph.D., 
Associate Professor, Mathematics and Statistics 
HONORS PROGRAM APPROVAL: 
 
 
       
Barry Falk, Ph.D., 










I would like to dedicate this thesis to my brother, Devin Hatchett, who constantly motivates and 




Table of Contents 
Dedication ...................................................................................................................................... 2 
List of Figures................................................................................................................................ 4 
Acknowledgments ......................................................................................................................... 5 
Abstract.......................................................................................................................................... 6 
Background ................................................................................................................................... 7 
Metabolic Syndrome............................................................................................................................... 8 
Insulin Resistance ................................................................................................................................. 10 
Functions of the Kidney ....................................................................................................................... 11 
Renal Complications of Metabolic Syndrome.................................................................................... 12 
Goals of this Thesis ............................................................................................................................... 13 
Microarray Analysis ............................................................................................................................. 14 
Meta-Analysis ........................................................................................................................................ 15 
Purpose......................................................................................................................................... 17 
Methods........................................................................................................................................ 18 
Data Collection ...................................................................................................................................... 18 
Studies Chosen for Analysis................................................................................................................. 18 
Study One: Dahl Salt-Sensitive Rats in Hypertension Study ............................................................. 19 
Study Two: Zucker Obese Rat Study ................................................................................................. 20 
Study Three: Insulin Resistance in a Transgenic Rat Strain .............................................................. 21 
Pre-Processing of Data ......................................................................................................................... 22 
Meta-Analysis ........................................................................................................................................ 23 
Determination of Significant Genes within the Meta-Analysis......................................................... 24 
Quality Check of Significant Genes .................................................................................................... 26 
Tissue Extraction .................................................................................................................................. 28 
RNA Isolation ........................................................................................................................................ 28 
Examining the Quality of the RNA ..................................................................................................... 29 
Reverse Transcription of RNA ............................................................................................................ 30 
Primer Design........................................................................................................................................ 30 
Quantitative Real-Time Polymerase Chain Reaction........................................................................ 32 
Data Analysis For Determining Gene Expression ............................................................................. 32 
Results .......................................................................................................................................... 34 
Discussion .................................................................................................................................... 38 
Appendices................................................................................................................................... 44 
Appendix 1............................................................................................................................................. 44 






List of Figures 
Figures 
 
Figure 1.  General Kidney Anatomy.  Retrieved from 
http://www.unckidneycenter.org/images/glomerulus.jpg on 4/07/14. ..........................................12 
Figure 2.  Example of a microarray slide, where each bead represents a distinct gene in the rat 
genome.  This figure shows more nucleotides per individual gene than the arrays used in 
this thesis.  Image source:  Dr. Terrie Rife, James Madison University............................... 14 
Figure 3. Venn Diagram showing the meta-analysis technique.  Each study has insulin resistance 
and the characteristics identified above.  The intersections show which genes were 
significant in the overlapping studies.  Gene A was significant in all three studies and thus 
should be examined further................................................................................................... 16 
Figure 4.  Gel showing the 5 primers and the housekeeping gene (B-actin).  In lane one, Ampd3 
was run. Lane 2 contains B-actin. Lane 3 contains Klk1c9. Lane 4 contains Mgmt, Lane 5 
contains the molecular weight marker.  Lane 6 contains RGD 1309350.  Lane 7 contains 




Table 1.  Criteria for diagnosing MetS based on differing criteria of various organizations. ...... 10 
Table 2.  Descriptions of the studies chosen for meta-analysis. ................................................... 19 
Table 3.  Primer sets used in qPCR............................................................................................... 31 
Table 4. Genes meeting the criteria for an average fold change of > 0.58496 or < -0.58496. ..... 34 
Table 5. Genes already associated with MetS, and remaining novel genes.  Remaining novel 
genes refers to their novelty to MetS association, not novelty in function........................... 35 
Table 6. Gene expression of treatment samples depicted as a percentage of the control. ............ 36 
Table 7. Average gene expression +/- a standard deviation. ........................................................ 36 





I would like to acknowledge and thank my advisor, Dr. Terrie K. Rife, for her constant 
support and guidance throughout this project. Without her continuing advice and encouragement, 
I would not have been able to complete this project.  She has given me the lab experience that 
will be integral in my later career pursuits. 
I would also like to thank one of my readers, Dr. Timothy Bloss, for dedicating his time 
serving on my committee.  He has been an influential member in bettering and expanding this 
project as it progressed. 
I would also like to thank my other reader, Dr. Janet Daniel, for her investment in this 
project and service on my committee.  Her knowledge of metabolism was integral to developing 
this project.  She has inspired my continued desire to work in the field of endocrinology through 
her Human Metabolism class. 
I would like to thank Dr. Nusrat Jahan for her extensive help with the statistical 
methodology of this thesis.  Her guidance and knowledge of the program R were integral in 
completing the statistical analysis required for this project.  The UBM group of Lauren van 
Reesema, Keith Zirkle, and Jonah Williams were also helpful in providing an excellent example 
to guide my project. 
Lastly, I am grateful for the support and encouragement of my friends and family for 




Metabolic syndrome is a clustering of risk factors that make a person more susceptible to 
cardiovascular disease and diabetes, and subsequently kidney disease.  The overall metabolic 
health of American society is decreasing at an alarming rate.  Metabolic syndrome is difficult to 
study due to its multi-factorial nature, which can vary from study to study.  This work utilizes a 
meta-analysis to examine the trends in changes of gene expression that occur in rat kidneys from 
three different models of metabolic syndrome.  Microarray studies used for this analysis were 
GSE4800, and GSE7193 obtained from the Gene Expression Omnibus, and E-MEXP-1695 
obtained from the European Bioinformatics Institute.  Following processing, 88 genes were 
found to be significant, including 73 upregulated genes, and 15 downregulated genes.  
Approximately 42.0% of the significant genes had already been associated with metabolic 
syndrome.  Five novel genes were chosen to examine in further detail using real time PCR.  
These genes include downregulated genes RGD1309350, and Klk1c9 and upregulated genes 
Stk32c, Ampd3, and Mgmt.  Preliminary qPCR results verified the trends found through meta-
analysis for Klk1c9, and Mgmt, but not for the remaining three genes.  Future work involves 












In recent years, the overall metabolic health of the general population has been steadily 
decreasing contributing to an exponential increase in disease and health care costs.  This 
decrease in metabolic health has been attributed to poor diets high in fat and sugar along with an 
increase in sedentary lifestyles (Hong et al., 2014).  It is thought that there is a genetic 
component to obesity and subsequent metabolic dysfunction as well.  As a result of this shift in 
diet and activity level, many more people are becoming obese, and developing health 
complications.  Due to this increased prevalence of metabolic disease the term metabolic 
syndrome (MetS) was generated to describe a clustering of risk factors for health complications 
such as kidney disease, cardiovascular disease (CVD), and stroke.  It is estimated that 20-25% of 
the world’s adult population have metabolic syndrome (Alberti, Zimmet, Shaw, & Grundy, 
2006).  Insulin resistance is also thought to underlie MetS, and in conjunction with other risk 
factors, can significantly increase a patient’s risk for type 2 diabetes mellitus (T2DM) (Grundy et 
al., 2004).  Patients with metabolic syndrome have a 5-fold greater risk in developing T2DM, 
and up to 80% of patients with T2DM will develop CVD (Grundy, 2007).  Patients with 
metabolic syndrome are at a high risk for renal complications such as microalbuminuria and/or 
chronic kidney disease (Locatelli, Pozzoni, & Del Vecchio, 2006).  Kidney damage (as signaled 
by microalbuminuria) is also an integral factor in cardiovascular disease risk assessment because 
many patients with microalbuminuria (especially diabetic patients) have increased 
atherosclerosis (Gobal, Deshmukh, Shah, & Mehta, 2011).  Patients with metabolic syndrome 
have a 2-fold higher chance of developing CVD (Grundy, 2007).  It is recommended that weight 
reduction and an increase in physical activity be used to combat the growing prevalence of such 
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disease (Grundy, 2012).  These factors contribute to the necessity of expanding this area of 
research. 
Metabolic Syndrome 
The term metabolic syndrome is a relatively new description for a group of risk factors that, 
when present together, can increase a person’s risk for coronary artery disease, stroke, type 2 
diabetes, and kidney disease.  Although this condition is rapidly increasing in prevalence, it is 
not yet clearly defined in the literature.  There are a variety of definitions of metabolic syndrome, 
coming from different organizations, which are summarized in the following discussion and in 
Table 1. 
The National Cholesterol Education Program’s Adult Treatment Panel III (ATP III) 
classifies metabolic syndrome using the following criteria: waist circumference > 102 cm (>40 
in) for men and > 88 cm (>35 in) for women, triglycerides (TG) ≥ 150 mg/dL, HDL cholesterol 
< 40 mg/dL for men and < 50 mg/dL for women, blood pressure ≥ 130/85 mmHg and fasting 
blood glucose level ≥ 110 mg/dL.  Metabolic syndrome can be diagnosed when 3 of the 
previously listed risk factors are present.  Although many patients meeting this criterion for MetS 
do have insulin resistance, it is not required in order to be diagnosed with MetS (Grundy et al., 
2004). 
According to the World Heath Organization, insulin resistance (as indicated by T2DM, 
impaired fasting glucose, or impaired glucose tolerance) is required in addition to two other 
MetS risk factors.  The risk factors include: high blood pressure (≥140/90 mmHg), plasma 
triglycerides ≥ 150 mg/dL (≥1.7 mmol/L), HDL cholesterol < 35 mg/dL (0.9 mmol/L) in men or 
< 39 mg/dL (1.0 mmol/L) in women, BMI > 30 kg/m
2
 and/or waist:hip ratio > 0.9 in men and > 
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0.85 in women, and urinary albumin excretion rate ≥ 20 µg/min or albumin:creatine ratio ≥ 30 
mg/g (Grundy et al., 2004).  
The European Group for the Study of Insulin Resistance (EGIR) requires insulin 
resistance in conjunction with two or more of the following: central obesity (waist circumference 
≥ 94 cm for males and ≥ 80 cm for females), dyslipidemia (triglycerides ≥ 2.0 mmol/L), 
hypertension (blood pressure ≥ 140/90 mm Hg, and a fasting plasma glucose ≥ 6.1 mmol/L 
(Bloomgarden, 2004). 
The International Diabetes Federation (IDF) defines metabolic syndrome as having 
central obesity (waist circumference defined by ethnicity-specific values) and two of the 
following: raised triglycerides (>150 mg/dL), reduced HDL cholesterol (<40 mg/dL for males, 
<50 mg/dL for females), raised blood pressure (systolic >130 mm Hg, diastolic >85 mm Hg), 
and raised fasting plasma glucose (>100 mg/dL or previously diagnosed T2DM) (Alberti et al., 
2006).  
This inconsistency in definitions further exemplifies the necessity of more research in this 
area of metabolism, and shows why its clinical determination is often complicated.  However, 
most epidemiological studies have used the ATP III definition based on its easy utility in the 
clinical setting (Singh & Kari, 2013).  Given the presence of such a wide array of components 
and criteria, a decision had to be made as to what criteria and definition would be used in this 
thesis to diagnose MetS.  The definition of MetS used in this study was made stringently so that 
it would be an inclusive mixture similar to most of the definitions: where two or more risk 
factors are occurring in conjunction with insulin resistance (in our case, each study has 3 risk 




Table 1.  Criteria for diagnosing MetS based on differing criteria of various organizations. 








Waist circumference ≥ 102 cm or 40 in (male), ≥ 88 cm or 35 in 
(female) 
TG ≥ 1.7 mmol/L (150 mg/dl) 
HDL-C < 40 mg/dL (male), < 50 mg/dL (female) 
Blood Pressure ≥ 130/85 mmHg 
Fasting plasma glucose ≥ 6.1 mmol/L (110 mg/dL) 




Waist:hip ratio > 0.90 (male), > 0.85 (female) or BMI > 30 kg/m
2
 
TG ≥ 2.0 mmol/L and HDL-C ≤ 0.9 mmol/L (male), ≤ 1.0 mmol/L 
(female) 
Blood Pressure ≥ 140/90 mmHg 
Microalbuminuria: Urinary albumin excretion ratio ≥ 20 µg/min or 
albumin:creatine ratio ≥ 30 mg/g 
Insulin resistance 






tolerance and 2 or 
more components 
European Group 
for the Study of 
Insulin 
Resistance 
Waist circumference ≥ 94 cm or 37 in (male), ≥ 80 cm or 31.5 in 
(female) 
TG ≥ 2.0 mmol/L and/or HDL-C < 1.0 mmol/L 
Blood Pressure ≥ 140/90 mmHg 
Fasting plasma glucose ≥ 6.1 mmol/L 
Insulin resistance 
as the top 25% of 
the fasting insulin 
values among non-
diabetic individuals 





TG ≥ 150 mg/dL (1.7 mmom/L) 
HDL < 40 mg/dL (1.03 mmol/L) in males, < 50 mg/dL (1.29 mmol/L) 
in females 
Blood Pressure > 130/85 
Fasting Plasma Glucose > 100 mg/dL (5.6 mmol/L) 
Central obesity and 




Although each organization has a slightly different definition of MetS, insulin resistance is a 
recurring factor in a majority of the definitions.  This suggests that insulin resistance underlies 
the pathology metabolic syndrome by some mechanism, and thus it is important to define insulin 
resistance and explain its role in the pathology of MetS. 
Insulin resistance is another term for reduced insulin sensitivity in tissues that are capable 
of responding to insulin.  When the tissues are insulin resistant, increased glucose transport does 
not occur after insulin stimulation, and thus glucose remains in the blood.  This often leads to a 
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state of hyperinsulinemia where more and more insulin is secreted in response to hyperglycemia.  
Often, the overproduction of insulin tires out the pancreatic beta cells (cells that produce insulin), 
and when they are no longer able to produce insulin, the patients becomes hyperglycemic 
(pertaining to high blood glucose) (Alberti et al., 2006). 
The presence of insulin resistance is often signaled by hyperglycemia and glucose 
intolerance, which are two diagnostic indices for T2DM.  Upon assessment of acute and chronic 
T2DM, it itself classifies as a risk factor for CVD.  In addition, insulin resistance independently 
has been linked to a risk of CVD, as well as a rise in blood pressure.  Insulin resistance has also 
been linked to obesity, where a rise in fat content correlates with increasing insulin resistance 
(Grundy et al., 2004).  Insulin resistance mediates many of the risk factors for MetS, which 
shows the prevalent role insulin resistance is playing in its diagnosis. 
  Patients with metabolic syndrome have a 5-fold increase in diabetes risk compared to 
healthy individuals, which contributes to an association of metabolic syndrome with a pre-
diabetic state (Stern, Williams, Gonzalez-Villalpando, Hunt, & Haffner, 2004).  Since metabolic 
syndrome is becoming an increasingly prevalent precursor to heart disease, diabetes, and kidney 
disease, the goal of this project is to examine genes that are likely to be influential in the 
pathology of metabolic syndrome in the kidney.  This could give valuable insight into possible 
causes of metabolic syndrome, which could aid in studying the various conditions that often stem 
from metabolic dysfunction. 
Functions of the Kidney 
The main function of the kidneys is to recondition the blood to remove toxins, and retain 
nutrients producing urine as the waste product.  Urine is composed of metabolic wastes that the 
body needs to move along with water.  Water is removed in specific quantities to regulate the 
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osmolarity of bodily fluids.  Blood flows through a series of glomeruli, which are tangles of 
blood vessels surrounded by a cup-shaped structure called the Bowman’s capsule.  The kidneys 
are efficient at filtering the blood, due to the high pressure on the glomerular capillaries.  The 
wastes that are filtered from the blood form urine.  Before the urine is fully formed, many solutes 
and water are reabsorbed into the blood.  The urine is collected in the renal tubule and later joins 
the collecting ducts to travel to the bladder for excretion (Frayn, 2010).  Figure 1 shows the 
general anatomy of the kidney, and the functional unit of the kidney, the nephron.  
 
Figure 1.  General Kidney Anatomy.  Retrieved from http://www.unckidneycenter.org/images/glomerulus.jpg on 
4/07/14. 
 
Renal Complications of Metabolic Syndrome 
Patients with metabolic syndrome are at a high risk for renal complications such as 
microalbuminuria and/or chronic kidney disease (Locatelli et al., 2006).  Metabolic syndrome 
patients have a 2.5-fold higher risk of CKD and a 2-fold higher risk of microalbuminuria as 
compared to a healthy individual (Singh & Kari, 2013).  Microalbuminuria occurs when small 
amounts of protein (albumin) are lost via the urine due to pathology in glomerular filtration, 
when it would normally be returned to the bloodstream when the kidneys are functioning 
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correctly.  The kidneys are at risk for damage from chronic kidney disease (CKD) in patients 
with metabolic syndrome as a result of atherosclerotic vascular damage (Okada et al., 2013).  
The pathologic effects of metabolic syndrome on the kidney can be manifested in the following 
ways: tubular atrophy, interstitial fibrosis, and global and segmental sclerosis.  It is hypothesized 
that the combination of insulin resistance, hypertension, dyslipidemia and inflammation result in 
increased expression of adipocytokines, angiotensin, inflammatory cytokines such as interleukin 
(IL)-6 and tumor necrosis factor α (TNFα), which results in renal fibrosis (Singh & Kari, 2013).  
The high blood glucose (hyperglycemia) noted in many cases of metabolic syndrome may also 
be contributing to glomerular damage.  Microalbuminuria has also been noted in individuals in 
this pre-diabetic state, which is of concern because it may indicate CKD.  A pre-diabetic state is 
one is which blood glucose levels are elevated, but not enough to be diagnosed as diabetes 
(Grundy, 2012).  Since a pre-diabetic state can lead to T2DM, the kidney is a valuable organ to 
study in relation to metabolic syndrome because diabetes can lead to diabetic nephropathy, 
which is a common microvascular complication of T2DM (Frayn, 2010).  These conditions can 
result in renal failure, making it necessary for the patient to receive dialysis to filter toxins and 
metabolic wastes out of the blood. 
 
Goals of this Thesis 
Based on the widespread pathologic effects of metabolic syndrome, this thesis aims to: 
1. Further understand the pathologic effects of metabolic syndrome on the kidney by examining 
changes in gene expression caused by metabolic syndrome in the kidney throughout the rat 
genome to determine which genes should be examined in further detail. 




Microarray analysis is used in this project to study changes in gene expression caused by 
metabolic syndrome that may lead to kidney disease.  Microarrays are a research tool aimed at 
indentifying patterns of gene expression among an entire genome.  Each microarray slide is 
printed with the entire genome of the organism of interest, using small fragments of 
complementary DNA (cDNA) for each gene.  The cDNA is arranged in a grid-like pattern 
allowing for each gene to have a precise location on the microarray slide (Figure 2).  There are 
two distinct types of microarray analysis: single-channel arrays and two-channel arrays.  
Microarray data from 3 different studies will be combined and analyzed in this thesis, from 
single channel arrays.  
 
Figure 2.  Example of a microarray slide, where each bead represents a distinct gene in the rat genome.  This figure 
shows more nucleotides per individual gene than the arrays used in this thesis.  Image source:  Dr. Terrie Rife, 




Messenger RNA (mRNA) is isolated and extracted from kidney tissues of both the wild-
type and experimental groups.  The mRNA is reverse transcribed into cDNA and is hybridized to 
the microarray slide.  The wild-type and experimental samples are each hybridized to different 
microarray slides in addition to rat genomic cDNA.  In a single channel array, the wild-type and 
experimental cDNA samples are tagged with a red florescent dye, while rat genomic cDNA is 
labeled with a green fluorescent dye.  The slides are then scanned to determine the ratio of red to 
green pixels for each gene.  The green genomic cDNA is a universal standard, so the ratios are 
treated as absolute levels of gene expression and are compared between the wild-type and 
experimental group to determine if a gene is upregulated or downregulated. 
Meta-Analysis 
A meta-analysis is a technique used to combine data sets from multiple different sources.  Since 
metabolic syndrome includes many factors contributing to its clinical diagnosis, a meta-analysis 
can be used to combine these factors and thus gain a wider understanding of the possible genes 
involved in metabolic syndrome.  There are now a large variety of studies related to metabolic 
syndrome or the components of it; many of which employ microarray technology to investigate 
genes related to distinct components of metabolic syndrome.  
However, based on the costly nature of using microarrays, these studies are often narrow 
in scope (investigate only one condition or aspect of a condition) and have small data sets.  Using 
a meta-analysis, the data for specific conditions as a whole can be combined and be directly 
compared although there are likely to be differences in experimental protocols.  This is an 
inexpensive way to investigate multivariate conditions such as MetS using data from studies 
more concentrated to a single factor of the condition.  Using a meta-analysis increases the sample 
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size and subsequently the statistical power of the results (Choi, Yu, Kim, & Yoo, 2003).  Figure 
3 demonstrates the technique of using a meta-analysis as applied to this thesis. 
Three different studies, each investigating a specific aspect of MetS, were used to analyze 
the common genes between the three studies, and determine changes in gene expression caused 
by risk factors for MetS.  The meta-analysis is used to determine which changes in gene 
expressions overlap between the studies.  Since all three risk factors can be present together and 
denote a MetS condition, genes that overlap in all three studies may be influential in the 
regulation and pathology of MetS.  For example, in Figure 3 below, while Gene B and Gene C 
may be significant in two of the three studies, only Gene A is significant in all three studies.  The 
conclusion drawn from this hypothetical data would be that Gene A could be playing a role in 
MetS, and thus should be further investigated. 
 
Figure 3. Venn Diagram showing the meta-analysis technique.  Each study has insulin resistance and the 
characteristics identified above.  The intersections show which genes were significant in the overlapping studies.  




Due to the increasing prevalence of MetS and its complications, metabolic disease has gained 
increased awareness and attention for the general public and scientists.  Because of its 
multivariate nature and multi-factorial effects, scientific literature has had significant difficulty in 
determining the exact mechanism underlying MetS and its pathogenesis.  Three studies, which 
are detailed in the Methods section of this thesis, were chosen to represent MetS.  For all of the 
studies, single channel microarray data for the kidney was available, and a revised statistical 
protocol from a previous study was used to isolate upregulated and downregulated genes.  This 
thesis aims to determine what genes are upregulated and which genes are downregulated in 
kidneys of rodent models with metabolic syndrome.  Once identified, further real-time PCR 
analysis will be completed to verify the accuracy of the meta-analysis data.  The answers to these 






In order to collect microarray data related to MetS, existing studies concerning various 
characteristics of MetS were obtained via the National Center for Biotechnology (NCBI) Gene 
Expression Omnibus (GEO) database and the European Bioinformatics Institute (EBI) 
ArrayExpress database.  Two studies from NCBI GEO database and one study from EBI 
ArrayExpress were chosen for analysis based on the following characteristics: 
1. Study used kidney tissue samples. 
2. Insulin resistance and at least two other symptoms of metabolic syndrome were evident 
in all rat models at the time of data collection. 
3. All studies were single channel Affymetrix microarrays so that they could be easily 
compared to investigate the entire rat genome. 
4. Raw data was available online. 
The raw microarray data was obtained via NCBI’s GEO2R or ArrayExpress and extracted 
into a comma-separated values (.csv) file.  This format of the data was compatible for statistical 
analysis using the program R, and Microsoft Excel. 
 
Studies Chosen for Analysis 
After a thorough search for studies meeting the above criteria was performed, three studies were 
selected for use in the meta-analysis.  All three studies used an Affymetrix Rat Genome 230 2.0 
One-Channel Array.  All three studies also investigated a total of 31099 genes via microarrays. 
 
19 





Rats Used Criteria for Relation 
To Metabolic 
Syndrome (in 




Link to Microarray Data 
1 GSE4800 Started at 
5 wks, fed 
for 8 wks 





levels, high blood 
pressure, and a high 
fasting blood 
glucose level 





2 GSE7193 12 wks 12 wk old 
male ZO 
rats and ZL 
rats 
Large waistline, 
high blood pressure, 
and a high fasting 
blood glucose level 
6 (3 ZL 













levels, high blood 
pressure, and a high 
fasting blood 
glucose level 
11 (5 normal 








Study One: Dahl Salt-Sensitive Rats in Hypertension Study 
Study one performed by (Yasui, Kajimoto, Sumiya, Okuda, & Iwai, 2007), used 13-week old 
male Lewis rats and 13-week old male Dahl Salt-Sensitive (DS) fed a high salt diet (8% NaCl) in 
order to study salt-sensitive hypertension.  Male DS rats and Lewis rats were fed the high salt 
diet starting at 5 weeks of age, and the treatment continued for 8 weeks.  The DS rats were fed a 
high salt diet to induce salt-sensitive hypertension.  Their goal was to narrow down the genes 
that may be involved in salt-sensitive hypertension in the kidney in the chromosome 10 
quantitative trait loci region.  Their control group in the microarray analysis included the Lewis 
rats on a high salt diet, compared to the treatment rats (DS rats on a high salt diet).  The 
treatment rats developed the following three metabolic syndrome criteria: high triglyceride level, 
high blood pressure, and a high fasting blood glucose level (Table 2).  They did two other 
microarray experiments; the data of which is available via GSE 4800.  They selected genes that 
 
20 
modulated expression more than 2-fold or less than 0.5 fold in all three of their studies.  They 
determined that 8 genes were differentially expressed by their criteria.   
After reverse transcription, PCR verification, and Northern blot analysis, it was 
determined that the expression levels of Ccl2 mRNA were 10-fold higher in the DS rats fed a 
high salt diet than in the Lewis rats fed a high salt diet.  This was the only gene whose trend was 
verified via PCR, showing that it was differentially expressed between DS and Lewis rats after a 
high salt diet, concluding that the gene is upregulated in the DS rats in response to a high salt 
diet.  Ccl2 is known to be involved in renal injury, and higher expression of Ccl2 could 
aggravate macrophage infiltration, which can ultimately result in an exacerbation of salt-
sensitive hypertension.  They concluded that this gene may be playing an influential role in 
hypertension in the kidneys.  
Why is this study applicable to this meta-analysis?  For our study, the DS rats on a high 
salt diet were used as the treatment and the Lewis rats fed a high salt diet were the control.  A 
total of 6 arrays were used from this study (3 DS arrays, and 3 Lewis arrays).  This study uses 
Dahl-Salt sensitive rats, which by definition exhibit hypertension, insulin resistance, 
hyperinsulinemia, and hypertriglyceridemia (Animal models of disease: Metabolic, renal, and 
cardiovascular.2011).  Although this study focuses on studying hypertension, the characteristics 
these rats exhibit fit our criteria for a diagnosis of MetS, making it an applicable study to include 
in the meta-analysis. 
Study Two: Zucker Obese Rat Study 
The study by (Song, Liu, Ressom, Tiwari, & Ecelbarger, 2008) used 12-week old male Zucker 
Lean (ZL) rats as the control rat and 12-week-old male Zucker Obese (ZO) rats as the treatment 
rat in an experiment studying obesity as it related to the development of type 2 diabetes.  Zucker 
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Obese rats have a deletion mutation in the leptin receptor, which causes misregulation of appetite 
and hunger.  These rats develop a large waistline, high blood pressure, and a high fasting blood 
glucose level (Table 2).  In addition to studying the difference in gene expression between ZO 
and ZL rats, the study also examines the effects of different compounds used as potential 
diabetes drugs, such as rosiglitazone and thiazolidinediones. 
Using the microarray data, 903 probe sets were determined to be significantly altered 
with at least a 1.5-fold change between the control and treatment groups.  There were 300 probe 
sets that were increased and 244 probe sets that were decreased in obese rats compared to lean 
rats.  Increased genes included the B-subunit of the epithelial sodium channel (ENaC), the 
thiazide-sensitive Na-Cl cotransporter, and aquaporin 3.  Decreased genes included angiotensin-
converting enzyme, type 1 (ACE1) (Song et al., 2008). 
Why is this study applicable to this meta-analysis?  For our study, 3 arrays from the ZO 
rats and 3 arrays from the ZL rats were used as the treatment and control respectively.  Zucker 
Obese rats were used to study obesity and T2DM.  Zucker rats by definition have the following 
characteristics: obesity, insulin resistance, hyperinsulinemia, and hypertriglyceridemia (Harlan 
Laboratories, 2014).  Although this study focused on the effects of obesity and diabetes, it is 
useful for this meta-analysis since the Zucker Diabetic Fatty (ZDF) rats used for PCR 
verification are also obese and diabetic. 
Study Three: Insulin Resistance in a Transgenic Rat Strain  
In a study by (Wallis et al., 2008) the cardio-metabolic syndrome (similar to our definition of 
metabolic syndrome) was examined using Brown Norway (BN) rats as the control rats and Goto-
Kakizaki (BN.GK-D1Wox18/D1Got254, a transgenic insulin resistant strain) rats as the 
treatment rats.  This study utilizes this type of rat to examine genes related to diabetes and 
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obesity, because GK rats carry a mutation in a G-protein receptor that is primarily associated 
with obesity.  These rats exhibit high triglyceride levels, high blood pressure, and a high fasting 
blood glucose level (Table 2). 
At the 12 and 24 week stage the congenic rats showed elevated blood glucose levels and 
hyperinsulinemia.  Six-month-old rats were used for microarray analysis.  According to the 
microarray data, a significant difference in transcription was observed for 478 distinct genes, and 
the trends were verified for 38 of the genes.  The results of this study identified a genetic basis of 
risk factors for the cardio-metabolic syndrome. 
Why is this study applicable to this meta-analysis? This study uses Goto-Kakizaki rats to 
investigate the cardio-metabolic syndrome.  Goto-Kakizaki rats naturally develop T2DM early in 
life, but they are not obese.  These rats are commonly used in studies investigating metabolic 
phenomena, and again meet our criteria for having metabolic syndrome.  Since T2DM is a 
common result of MetS, this study adds to our meta-analysis with regards to the later stages of 
MetS. 
Pre-Processing of Data 
The data was processed by a previous group of students involved in the Undergraduate Research 
in Biology and Mathematics (UBM) program (Lauren van Reesema, Keith Zirkle, and Jonah 
Williams) and Dr. Nusrat Jahan.  The raw data in its entirety was extracted from either the NCBI 
GEO Omnibus database or EBI ArrayExpress and converted into .csv files for later use with 
Microsoft Excel and the program R for statistical analysis.  For each of the three studies, separate 
.csv files were generated for the specified wild type and treatment data. 
The resulting data was then quantile normalized before it was individually analyzed via 
the program R.  Quantile normalization is performed so that all of the arrays have the same 
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distribution, shape and similar spread.  Next, for each gene, a t-test was performed to determine 
individual significant differences in gene expression.  This analysis resulted in a test statistic to 
account for study variation and a p-value for each gene.  
 The statistical program R is used for analysis of microarray data.  Before any statistical 
analysis can be performed, the data were pre-processed.  The pre-processing included averaging 
gene duplicate values, log-2 base transformation and quantile normalization of the data.  The 
original data are right skewed, but all statistical tests require data to have at least approximately 
normal distribution.  Log transformation is a technique that makes right skewed distribution 
more symmetric by minimizing the scale of differences between values.  With this technique, if 
the gene signal intensity is very similar between the treatment and the control, the treatment to 
control ratio will be close to one, and the log2(1) is equal to 0.  If the treatment signal intensity is 
larger than the control, the ratio will be greater than one and log transformation will produce a 
positive number, signaling an upregulated gene.  On the other hand, if treatment signal intensity 
is smaller than the control intensity, a negative number will result signaling a downregulated 
gene. 
Mean log(gene expression) =  Mean log(treatment expression) – Mean log(wild-type expression) 
Meta-Analysis 
The meta-analysis performed in this project was performed by Dr. Jahan, using the program R 
and a code presented in Appendix 1.  An effect size (u) was calculated for each gene using the 
following formula, where ym is the mean treatment gene expression of the gene m, and xm is the 
mean gene expression of the wild-type: 
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The effect size represents the standardized mean difference in gene expression for the 
treatment and wild-type rats.  The mean gene expression of the control is subtracted from the 
mean treatment gene expression. This is then divided by the pooled standard deviation and a 
correction factor (si
pool
).  Using a pooled standard deviation accounts for the variability in the 
three studies and standardizes the sample sizes of the studies.  The correction factor is used to 
ensure that the denominator is large enough to not artificially inflate the meta-Z value.  The 
correction factor used is the 90
th
 percentile point.   
The meta-Z statistic is calculated for each gene using the mean and variance.  The mean 
is divided by the square root of the variance.  The purpose of the meta-Z value is to determine 
the threshold value for significant genes corresponding to a specified quantile or cut off point 
(Hu, Greenwood, & Beyene, 2005).  The meta-Z values were then used to determine the 
statistical significance of each gene. 
Determination of Significant Genes within the Meta-Analysis 
Genes were considered to be significantly upregulated if the meta-Z score was greater than or 
equal to +1.8888 and were considered to be downregulated if the meta-Z score was less than or 
equal to -2.054.  These meta-Z cut off values were assigned stringently in order to minimize the 
presence of false positives and negatives.  In order to determine the meta-Z cut offs, the 
difference between the meta-Z and the perm-Zs (permuted meta-Zs) were taken into account.  
Meta-Z cutoff values of 1.8888 and -2.054 were found using a difference of 2 between the true 
meta-Z and the average of the permuted meta-Z.  The perm-Zs are calculated in the same way 
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that the meta-Zs are calculated, but used the random permutation of the original data.  
Permutation is described further in the next paragraph with regards to the false discovery rate.  If 
a gene is not different between the treatment and control, then the random permutation of the 
data will produce perm-Z values that would be very different from the meta-Z values (Hu et al., 
2005).  If a gene is significant based on permutation, it can be concluded that the gene is not 
significantly different between the treatment and wild-type samples and its significance in the 
permuted data is purely due to random chance. 
The false discovery rate (FDR) method can be used to control the amount of false 
positive genes in the data set.  The FDR is determined by dividing the number of expected false 
positive genes by the number of truly significant genes.  The number of truly significant genes 
must be estimated since it is unknown.  This means that the FDR is also estimated using a 
permutation method.  This method is described by (Tusher, Tibshirani, & Chu, 2001).  
Permuting the data rearranges it to account for every possible scenario of gene expression.  A 
weighted average, weighted variance, and a meta-Z statistic are generated for each gene in each 
permutation.  Since the data is permuted β times, there are β permuted meta-Zs for each gene.  
The permuted meta-Z values are arranged from smallest to largest within each permutation and 
using the same threshold quantile that is used to identify significant genes from the meta-Zs, 
significant genes can be determined within each permutation.  These significant genes represent 
the false positives, since the permuted data should not have differential effects.   
In cases where gene expression is inaccurately reported as significantly different, a type 1 
(false positive) error occurs (Storey & Tibshirani, 2003).  Although in most statistical tests a 
significance level of 0.05 is used to determine the error rate, in microarray studies an alternate 
method must be used due to the large amount of genes being tested at once.  Since approximately 
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30,000 genes are being tested simultaneously, the error rate of each gene is combined producing 
an overall large error rate.  For example, when testing 30,000 genes each with an error rate of 
0.05, there would be 1,500 expected false positives.  This error rate is way too large for the study 
to have any statistical significance and relevance. 
Quality Check of Significant Genes 
In order for genes to truly be considered significantly upregulated or significantly 
downregulated, some additional parameters were put in place to ensure that these significant 
genes made biological sense.  The first criterion was that the average fold change for all three 
studies was at least a 1.5 fold difference between the treatment animals and the wild-type 
animals.  This was used in order to determine whether or not the genes were biologically 
significant, using the following equation: 
                                                          log2(1.5) = 0.58496 
This means that the average fold change of significant genes must be ≥ 0.58496 or ≤ -0.58496.  
The second criterion was that for a gene to be deemed upregulated, it must have a fold change ≥ 
0.58496 in at least two of the three studies, and must have a positive fold change in the third 
study.  For a gene to be deemed downregulated, it must have a fold change ≤ -0.58496 in at least 
two of the three studies, and must have a negative fold change in the third study.  This ensures 
that the average fold change is not artificially inflated or deflated based on a particular study.  
There are many possible scenarios that can be considered in regards to the previously described 
criteria.  For example, a gene could be really highly upregulated in one study, but not quite 
upregulated enough in the other two studies to be statistically significant.  Since the first study is 
inflating the average expression of the gene, this gene would not be retained in the list of genes 
to further investigate since it does not meet our criteria that a gene must be significant in at least 
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2 of the three studies and follow the general trend for gene expression in the third study.  
Another case could be that a gene is highly upregulated in two of the studies, but downregulated 
in the third study.  This gene would also not be included in the list of genes to analyze further 
since it does not meet the specified criteria. 
For example, the gene titled Syt10 (synaptotagmin X) meets our statistical cutoff value 
for the meta-z statistic to be called statistically significant and has an overall gene expression of 
1.5 fold for all three studies, as seen by its average fold change of 0.808.  The fold change for 
study one is 0.877, and the fold change for study two is 1.309.  These positive values (>0.58) 
support the conclusion that this gene is upregulated.  However, the fold change for study three is 
0.239, which still shows a slight upregulation, but not enough to meet our criteria of 0.58 (0.239 
< 0.58).  Since all three studies agree at this basic biologic level (upregulation) even though the 
third does not, it will be retained in the list of genes for further examination. 
 To carry out this screening, any gene with a fold change < 0.58496 or > -0.58496 was 
flagged in study one.  Then, any gene with a fold change < 0.58496 or > -0.58496 and was 
flagged in study two.  If it had been flagged in both studies one and two, it was entirely ruled out 
because it did not meet our criteria (since it would be out in two of the three studies).  The same 
criteria were used for study three.  Again, if it was < 0.58496 or > -0.58496 it was flagged, and if 
it had been previously flagged in either study one or study two (or both studies) it was ruled out 
overall. 
Next, some genes were thrown off simply because we were unable to determine their 
biological function.  Lastly, genes that had already been associated with metabolic syndrome 
were excluded from analysis, since this thesis aims to find novel genes that could be influential 




In order to verify the gene expression changes in these novel genes, tissues were obtained from 
Zucker Diabetic Fatty rats fed a 66% fructose diet or a standard diet for 10 weeks while 
monitoring their blood glucose and insulin levels.  Zucker Diabetic Fatty rats exhibit type 2-
diabetes, hyperlipidemia, glucose intolerance, obesity, and hyperinsulinemia (Animal models of 
disease: Metabolic, renal, and cardiovascular.2011).  The rats were characterized as diabetic at 
the time of tissue extraction by their marked hyperglycemia and hyperinsulinemia.  Kidney tissue 
was harvested by Divya Bansal, a former graduate student in the lab.  These tissues were 
surgically removed and stored in 3-4 mL of RNA later® solution to inhibit RNase activity.  The 
tissues were stored in this solution for two days at 4°C, then transferred to a new tube and stored 
at -80°C until use. 
RNA Isolation 
To study gene expression, RNA was isolated from the kidney tissue by Divya Bansal using the 
TRIzol method.  Four basic steps were used in the process of RNA isolation: breaking open the 
kidney cells, preparing the RNA, determining the concentration of the prepared RNA, and 
checking the RNA for degradation using gel electrophoresis.  Throughout this process, care was 
taken to avoid RNase activity by using RNAZap (Ambion) detergent wipes to chemically treat 
everything that could have potentially come in contact with the sample.   
To homogenize the kidney tissue, approximately 500 µL of TRIzol reagent per 50-100 
mg of tissue was added to a dounce homogenizer in order to lyse kidney cells.  The kidney 
sample was dissolved in the TRIzol reagent as quickly as possible to prevent degradation of the 
sample by RNases.   
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After homogenization, the sample was moved to a RNase free 15 mL tube and incubated 
at room temperature for 5 minutes.  Approximately 200 mL of chloroform per one mL of TRIzol 
reagent was added to the tube and shaken vigorously for 20 seconds.  This mixture was 
incubated at room temperature for an additional 5 minutes.  Centrifugation at 12,000 × G at 4°C 
for 15 minutes was used to pellet the cells by dividing the hydrophilic RNA from the 
hydrophobic proteins and bulkier DNA.  The upper aqueous clear layer contains the RNA and 
was placed in a new tube with 500 mL of isopropanol per one mL of TRIzol reagent used to 
precipitate the RNA.  This tube was vortexed and incubated at room temperature for 5 minutes, 
then centrifuged at 12,000 × G at 4°C for 8 minutes.  The supernatant was poured off, and one 
mL of 75% ethanol per one mL of TRIzol reagent was added to the pellet.  The sample was then 
centrifuged at 7,500 × G at 4°C, and the ethanol was poured off.  To remove the remaining 
ethanol, the sample was centrifuged again for one minute and the remaining ethanol was pipetted 
off.  The sample was then dried in the fume hood for approximately 5 minutes to allow the 
remaining ethanol to evaporate.  Once the samples were dried the RNA was resuspended in 50 
µL of RNA Storage Solution and stored at -80°C. 
Examining the Quality of the RNA   
To quantify the isolated RNA, the Nano-vue spectrophotometer was used to measure the 
absorbance of the sample at 260 nm (A260) and 280 nm (A280), and determine the concentration 
of the isolated RNA.  The quality of the RNA was determined using a ratio (A260/A280), which 
represents the ratio of nucleotide absorbance and protein absorbance.  Pure RNA should have a 
A260/A280 of 2.0-2.2, but any ratio over 1.9 was considered acceptable RNA quality. 
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To ensure the RNA quality, the RNA was run on a 1.2% agarose gel.  Two distinct bands 
are shown for good quality RNA:  a 28S band and a 18S band.  These represent the large and 
small subunits of ribosomal RNA.  The 28s band appears twice as bright as the 18S band.   
 
Reverse Transcription of RNA 
Once the RNA was deemed to have adequate quality, it was reversed transcribed from RNA into 
cDNA using a Superscript II Invitrogen kit.  A mixture of 5 µg of RNA, 2 µL of random 
hexamers, 1 µL of dNTPs, and nuclease free water was added together to make a total volume of 
10 µL.  The sample was then incubated at 70 °C for five minutes, and placed on ice for one 
minute to denature the RNA and primers.  Next, a mixture of 2 µL of 10x RT buffer, 2 µL of 0.1 
M DTT, 2 µL of 50 mM MgCl2, and 1 µL of RNase out inhibitor was added and the sample was 
incubated for two minutes.  Next, 0.5 µL of 50 units/µL Superscript II RT was added to the 
sample, which was then incubated at 42°C for 50 minutes.  Lastly, 0.5 µL of 100 units/µL RNase 
H was added to the sample, which was then incubated at 37°C for 30 minutes.  The samples were 
then stored at -20 °C until quantitative real-time PCR could be performed. 
 
Primer Design 
In order to verify the gene expression of the chosen novel genes, primers specific to each gene 
had to be designed.  The NCBI Primer Blast program was used to accomplish this 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?LINK_LOC=BlastHome).  The 
mRNA sequence was located and entered into the program.  The following parameters were 
changed from the defaults: PCR product size (70-300 bp) and melting temperature (57° C - 63° 
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C, with optimal melting temperature at 60° C).  The returned forward and reverse primer 
sequences were checked to make sure that they spanned at least one intron, and that the 
sequences did not match anything else in the genome besides the gene being amplified. 
 
Table 3.  Primer sets used in qPCR. 




5’-AAC CCT AAG GCC AAC CGT GAA AAG-3’ 






















RGD 1309350 Fwd 





 Figure 4 shows a DNA gel of the primers sepcified above. A one kilobase ladder was 
used, and 12 µL (including 6X loading dye) of each primer solution was loaded in each well. 
 
Figure 4.  Gel showing the 5 primers and the housekeeping gene (B-actin).  In lane one, Ampd3 was run. Lane 2 
contains B-actin. Lane 3 contains Klk1c9. Lane 4 contains Mgmt, Lane 5 contains the molecular weight marker.  




Quantitative Real-Time Polymerase Chain Reaction 
To amplify DNA containing the genes of interest and B-actin, quantitative real-time polymerase 
chain reaction (qPCR) was used.  A fluorescent dye called SYBR green is used to identify 
double-stranded DNA, thus inducing a brighter fluorescence as amplification continues. 
 To perform qPCR on the various samples, a master mix containing 1X SYBR green 
(enzymes and a dye that fits between double stranded DNA), and 0.2 µM forward and reverse 
primers for B-actin, Mgmt, Ampd3, Klk1c9, RGD1309350, or Stk32c was made.  The various 
primer sets used are presented in Table 3.  For each reaction, components were added in the 
following proportions: 10 µL of SYBR green master mix, 2 µL of 2mM primer, 2 uL of cDNA 
and 6 uL of water totaling 20 uL for each reaction.  Each gene was amplified with its specific 
primer for each of the three control samples, and each of the 4 treatment samples.  The reactions 
were then run on a Bio Rad Opticon Monitor CFX96 Touch™ Real-Time PCR Detection System 
(185-5196) with the following cycling conditions: 50°C for 2 minutes, 90°C for 2 minutes to 
denature cDNA and activate enzymes, followed by 50 cycles of: 95°C for 15 seconds, 60°C for 
30 seconds, with a plate read at 60°C, which was used to analyze the data in regression mode.  
After the 50 cycles, the temperature was lowered to 60°C for 10 minutes.  The machine then 
constructed a melting curve starting at 76°C, taking measurements every 0.2°C up to 98°C.  
After the amplification was complete, the products were run on a 2% agarose gel to confirm that 
the correct cDNA fragments were amplified (Figure 4). 
Data Analysis For Determining Gene Expression 




T method, or the Livak method.  This method assumes that both 
the target gene and the housekeeping gene are amplified with efficiencies near 100% and within 
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 Next the ΔCT of the test sample was normalized to the ΔCT of the calibrator: 
ΔΔCT=ΔCT(test)- ΔCT(calibrator) 





T=Normalized expression ratio 
 Once the normalized expression ratio is obtained, it is converted into a percentage.  This 
percentage is indicative of the percent of the control expression that the treatment is expressing.  
For example, if the normalized expression ratio is 0.66, it can be concluded that the gene is 
expressed at 66% of the control expression.  This gene would be considered downregulated 




To determine what genes may be influential in the pathology of metabolic syndrome, a meta-
analysis of 3 microarray studies was performed.  After running the R code presented in Appendix 
1 and before screening for the significant genes, there were 12,328 genes in common in this 
meta-analysis.  Based on the meta-Z cutoffs of 1.8888 and -2.054, 597 genes were found to be 
significant: 551 of these genes were upregulated, and 46 of the genes were downregulated.   
After screening the genes to determine which ones had an average fold change for all 
three studies that was at least a 1.5 fold difference between the treatment animals and the wild-
type animals, 158 genes remained (this list of genes is available in the Appendix 2).  Of the 158 
genes, 135 were upregulated, and 23 were downregulated (Table 4).  After screening the gene list 
according to the fold change in study one, 18 of the 158 genes were flagged because they did not 
have a fold change that was changed by 1.5 fold in study one.  After screening the gene list 
according to the fold change in study 2, 51 of the 158 genes were not changed by 1.5 fold in 
study two (2 of which had already been flagged in study one). After screening the gene list 








Table 4. Genes meeting the criteria for an average fold change of > 0.58496 or < -0.58496. 
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Genes With a Fold Change of 1.5-fold or Greater 
Upregulated Downregulated 
Havcr1, Scg2, RGD1562844, Eps8l3, Pthlh, C4bpb, Socs2, Clcf1, Thsd7b, 
Atpbd3, Kntc1, Fezf2, Gkn2, Clu, Hfe2, RGD1565709, Ckap2, Traf4af1, 
Prl3d1, LOC500118, Tmsb10, Mfap5, Abra, Adamts1, Dscc1, Ctsw, Timp1, 
Fcrls, Ttc25, Dfnb59, Dlgap5, Tnfrsf12a, Mgmt, RT1-Db1, Fetub, 
LOC290595, Ltbp2, Ttk, Rbm11, Cox6a2, Tekt1, LOC691979, Mbnl3, 
Clec2d, Pemt, Ccna2, Xkr4, Syt10, Ptgs2, C3, Prc1, Wtap, Mfap3, 
RGD1561849, Kcne1, Krt25, Cd8a, Tekt5, Gpx7, Fes, Ccl2, Casp4, Apoa1, 
Mpp3, RGD1563091, Arhgap11a, RGD1310862, Cox15, Mfap4, Lum, 
LOC378467, Nkg7, P2rx4, Col8a1, Pqlc3, Ptprz1, Spp1, RGD1559980, 
Sass6, Asns, Lsp1, Nipsnap3a, Eml2, S100b, Ubash3b, Slc18a1, Pmf1, 
Mical1, Tap1, Trpv1, Slc15a3, LOC497995, Depdc1, Fgb, Rftn2, Rrm2, Gda, 
LOC654482, Psmb9, Dclk1, Samsn1, Tdrd1, RGD1311558, Rab19, Kcnip3, 
Bin2a, Pcp4l1, RGD1305713, Cds2, Grem1, Pycard, Itih1, Bub1, Jrk, Col3a1, 
Athl1, Ccl20, Cmtm3, Slc7a7, LOC503175, RGD1565844, Cebpa, 
RGD1307621, C1qb, Ampd3, Actn3, Ccdc80, Cxcl10, Obfc2a, Fgr, Agap2, 
Lgals3bp, Tmed6, Hck, Cks2 
 
Abcb11, Rnf40, F2, Snap25, 
Bmp15, F5, Apoc1, Nell1, 
Mlc1, Serpinc1, Cep78, Grhl3, 
Krt14, Rp1h, Rbp4, Mrgprg, 
Scgb1c1, Slc22a13, 




After removing genes that we were unable to determine their biological function, there 
were a total of 88 genes (73 were upregulated and 15 were downregulated) (Table 5).  Lastly, 
after genes that had already been associated with metabolic syndrome were excluded from 
analysis 51 genes remained.  A total of 37 out of the total 88 genes used for analysis had already 
been associated with MetS in the literature (Table 5). This means that 42.0% of the significant 
genes had already been associated with MetS.  The 51 novel genes can be seen in Table 5. 
Table 5. Genes already associated with MetS, and remaining novel genes.  Remaining novel genes refers to their 
novelty to MetS association, not novelty in function. 
Genes Already Associated with MetS Remaining Novel Genes 
Hfe2, Havcr1, Spp1, Athl1, Rrm2, 
Kcnip3, Ccl2, C1qb, Pthlh, 
Tnfrsf12a, RGD1563091, Ccl20, 
Socs2, C4bpb, RT1-Db1, Timp1, 
Fes, Tap1, Serpinc1, Hsd3b6, 
Snap25, Mlc1, Mfap5, Psmb9, 
Ltbp2, Col8a1, Lum, Grem1, Ptgs2, 
Clcf1, Ccna2, Clu, Abcb11, Rbp4, 
Cyp2c, Rp1h, Pemt 
Abra, Ampd3, Arhgap11a, Atpbd3, Casp4, Ccdc80, 
Cep78, Ckap2, Cmtm3, Dclk1, Dscc1, Eml2, Eps8l3, 
Fetub, Gkn2, Grhl3, Jrk, Klk1c9, Kntc1, Krt25, 
Lgals3bp, LOC500118, LOC654482, Mgmt, Mrgprg, 
Nell1, Nipsnap3a, Pcp4l1, Pmf1, Pqlc3, Prc1, Prl3d1, 
Ptprz1, Rab19, Rbm11, Rftn2, RGD1307621, 
RGD1309350, RGD1311558, RGD1562844, 
RGD1565709, Sass6, Scg2, Scgb1c1, Slc15a3, Stk32c, 




Five genes were chosen as novel genes in relation to MetS that will be investigated 
further.  The five chosen genes are: Ampd3, Klk1c9, Mgmt, RGD1309350, Stk32c.  These genes 
were chosen based on their role in metabolism.  A majority of the genes can be classified as 
having to do with an amino acid’s role in metabolism or DNA packaging.  Some genes were 
simply chosen for their statistical characteristics.  RGD1309350, Klk1c9, and Stk32c are 
expected to be downregulated and Ampd3, and Mgmt are expected to be upregulated (Table 8). 
Preliminary PCR data and subsequent analysis using the Livak method described in the 
Methods is shown in Table 6.  The values in the table represent the percentage of the treatment 
compared to the control.  For example, a value of 0.66128 means that the treatment’s gene 
expression is 66.128% of the controls gene expression, and thus will be considered 
downregulated. 
Table 6. Gene expression of treatment samples depicted as a percentage of the control. 
Primer Ampd3 Klk1c9 Mgmt RGD1309350 Stk32c 
Treatment 1 66.128 % 122.0171 %  217.8472 % 57.4349 % 464.8719 % 
Treatment 2 74.9154 % 103.6761 % 317.8472 % 2208.508 % 516.7023 % 
Treatment 3 86.9545 % 67.6932 % 710.2532 % 46.6516 % 36.7122 % 
Treatment 4 0.006746 % 2.0152 % 38.1124 % 1.8136 % 2.0751 % 
 
If the four treatments are averaged, the average gene expression can be obtained and used 
to determine whether the gene is upregulated or downregulated.  The average gene expressions 
are as follows: Ampd3 is 0.571681, Klk1c9 is 0.738504, Mgmt is 3.210156, RGD1309350 is 
5.78602, and Stk32c is 2.550904 (Table 7). 
Table 7. Average gene expression ±  a standard deviation. 
Primer Ampd3 Klk1c9 Mgmt RGD1309350 Stk32c 
Average 57.168 ± 38.6 % 73.850 ± 52.9 % 321.016 ± 284.1 
% 
578.602 ± 1086.9 
% 

















Ampd3 upregulated 0.608 1.12, 0.61, 0.091 2.78 57.17 % 




Mgmt upregulated 0.880 





RGD1309350 downregulated -1.241 





Stk32c downregulated -1.948 









The complex nature of metabolic syndrome is multi-faceted, which has been influential in 
increasing the amount of research and attention being devoted to this disorder.  This thesis aims 
to elucidate some of the factors that may be playing a role in its pathology by studying gene 
expression.  Overall, the purpose of this thesis is to determine what genes may be influential in 
the development and progression of MetS in the kidney. 
The purpose of using a meta-analysis to study the effect metabolic syndrome has on gene 
expression is to gain statistical power.  Since metabolic syndrome is a multi-factorial disease, a 
meta-analysis is used to make a stronger and broader conclusion about the disease by examining 
studies with different components of the disease.  By combining the results of these studies, the 
statistical power is increased which leads to a stronger conclusion about the regulation of gene 
expression by metabolic syndrome.  Due to limited amounts of available microarray data, not all 
aspects of metabolic syndrome could be addressed in this thesis.  However, since 37 out of 88 
(42.0%) genes were already associated with metabolic syndrome, it seems that the methodology 
used in this meta-analysis is valid. 
When analyzing the data by fold change to ensure that the genes were actually 
biologically significantly upregulated, the genes had to have significantly upregulated or 
significantly downregulated fold changes in 2 of the 3 studies and follow the same trend in the 
third study.  When performing this step, many of the genes had significant fold changes in 
studies one and two, but were thrown off in the third study.  This could be due to the length of 
diet treatment of the rats in the studies, with the third study treating the rats the longest.  This 
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could mean that the rats in that study were farther along in their progression of MetS, which 
could differentially affect gene expression. 
Although there are many advantages to using meta-analyses, there are also some 
disadvantages.  Due to the fact that different laboratories performed the different studies used in 
the meta-analysis, it is possible that there is some variation in the protocols used for microarray 
analysis.  Other factors that could influence the accuracy of the meta-analysis include different 
technologies, different techniques and/or accuracy of microarray hybridization, and differences 
in the treatment of animals.  Also, since the technique of a meta-analysis examines so many 
genes at once (12,328 in this case), there is a possibility that genes are upregulated or 
downregulated by random chance.  Although we were stringent in the statistical analysis of this 
data, the random chance present in this study could be influencing gene expression and thus 
could be a source of error.  Human error is of course a possibility in any experiment, and could 
be contributing to the discontinuity of the data.  These factors could account for some of the 
inconsistencies observed in the data. 
The trends in gene expression were verified in 2 of the 5 chosen genes via real-time PCR.  
We used a fourth animal model for PCR verification.  As mentioned in the Methods section, each 
study used a different type of rat to examine gene expression.  Our lab used Zucker Diabetic 
Fatty rats to verify the gene expression observed in the meta-analysis, so the genetic differences 
in the rats could be influential in their gene expression patterns. 
Another topic worth noting is the role that hypertension could be playing in metabolic 
syndrome.  In this study, it is not considered as a separate factor that can occur in MetS, but 
hypertension may actually have its own independent effects on kidney function, separate from 
the effects triggered by metabolic syndrome.  All of the rat models used in the three chosen 
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studies exhibited high blood pressure, which show their link to hypertension.  Since the rats used 
for PCR verification were not hypertensive, the effects of gene expression in the kidney can be 
soley attributed to metabolic syndrome pathogenesis, whereas in the studies used to gather the 
microarray data this distinction cannot necessarily be made.  The microarray studies could show 
a bias towards the effects of hypertension on the kidneys since the rats used in all three studies 
exhibited high blood pressure, whereas the Zucker Diabetic Fatty rats used for PCR verification 
do not exhibit high blood pressure.  Although the ZDF model was able to verify two genes from 
the meta-analysis, there could be some false negatives in the PCR data resulting from the effects 
of hypertension independently.  Perhaps using a hypertensive diabetic rat model would ensure 
that all influential genes are PCR verified. 
The two genes that were verified are Klk1c9 and Mgmt.  Klk1c9, Kallikrein 1-related 
peptidase C9, encodes a protein that exhibits serine-type endopeptidase activity and is involved 
in the positive regulation of vasoconstriction.  Klk1c9 was significantly downregulated in studies 
one and two, and followed the trend for downregulation in study three.  Thus, this gene was 
expected to be downregulated, which agrees with the PCR results that Klk1c9 was expressed at 
73.850% of the control. 
In a study by Yamamuro, rats exposed to a tickling stimulus had increased expression of 
Klk1c9 and reduced amylase production (Yamamuro et al., 2013).  The reduction of amylase by 
submandibular glands could have implications for the digestion of carbohydrates, which links 
this gene to metabolic dysfunction.  According to the Rat Genome Database, this gene has also 
been associated with cardiovascular disease.  Since CVD is a common complication of MetS and 
T2DM, this gene could be influential in the end-stage of MetS. 
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Another study identified a broad chromosome 1 region around Klk1 that was influential 
in regulating blood pressure levels.  Since high blood pressure is one of the factors used to 
denote MetS in our project, it is not surprising that this gene was verified as being downregulated 
in the treatment rats compared to the control rats, which could mean that it is less active in 
controlling blood pressure in rats with metabolic syndrome (Yasui et al., 2007).  
O-6-methylguanine-DNA transferase (Mgmt) was significantly upregulated in all three 
studies, which agrees with the preliminary PCR data that it is expressed 321.016 % of the control 
in the treatment.  Mgmt, which encodes a protein that exhibits calcium ion binding and 
methylated-DNA-[protein]-cysteine S-methyltransferase activity.  It is also involved in DNA 
dealkylation and DNA repair (Laulederkind et al., 2013).  DNA repair is an important step in 
DNA replication, where mutations can be the cause of disease.  
Mgmt could be influential in the pathology of MetS since obesity and metabolic 
dysfunction have a founded genetic component.  The Rat Genome Database also cites that Mgmt 
is associated with neurologic disease.  In many cases of MetS (especially those that evolve into 
T2DM) patients experience peripheral neuropathy, which is loss of sensation caused by damage 
to neurons.  This links Mgmt to MetS since it is involved in DNA repair and neurologic disease, 
which can occur in the pathology of MetS. 
Although the remaining genes trends were not verified in PCR, some of them could 
possibly still be contributing to metabolic syndrome pathogenesis.  The general functions of the 
unverified genes will be briefly discussed, to give some context as to why they were chosen for 
this project.  
Adenosine monophosphate deaminase 3 (Ampd3) was significantly upregulated in 
studies one and two, and followed the general trend for upregulation in the third study, which 
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was not supported by the PCR percentage of +/- 57.168 %.  Ampd3 is a gene that encodes a 
protein that exhibits AMP deaminase activity, and is involved in AMP catabolism.  It also 
participates in the purine metabolic pathway and has been previously associated with heart 
disease and stroke (Laulederkind et al., 2013). 
RGD1309350 (similar to transthyretin (4L369)) was significantly downregulated in all 
three studies, but this was not supported by the PCR percentage of +/- 578.602 %.  RGD1309350 
encodes a protein that exhibits hydroxyisourate hydrolase activity and is involved in the purine 
nucleobase metabolic process (Laulederkind et al., 2013). This gene was chosen for its possible 
role in epigenetics.   
 Stk32c was significantly downregulated in studies one and three, and followed the trend 
for downregulation in study two, which did not agree with the PCR percentage of +/- 255.090 %.  
Stk32c encodes a protein that exhibits ATP binding and protein serine/threonine kinase activity  
(Laulederkind et al., 2013).  The phosphorylation step could be influential in signaling cascades 
related to MetS.  Stk32c was the most inconclusive gene with regards to the PCR data (gene 
expression was greatly varied among the 4 treatments), suggesting a possible error with the 
primer used for its amplification.  Stk32c was expected to be downregulated, which disagrees 
with the average PCR data, but further PCR analysis in necessary to confirm this finding. 
Based on the discontinuity of the PCR data with the statistical expectations, future work 
includes continuing to collect PCR data to verify the upregulation or downregulation trends.  
This project could be expanded is by changing the definition used to define and diagnose 
metabolic syndrome.  Since the literature is so inconclusive as to the exact criteria needed to 
diagnose a person with MetS, there may be some value in tweaking the criteria used to include 
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studies in the meta-analysis.  This could potentially result in more applicable studies that when 
included in the meta-analysis, may uncover more novel genes to investigate.   
 Since the gene expression data is still preliminary, a much larger pool of data may be 
necessary to verify the trends already observed through the PCR data.  As future work reveals 
more consistent PCR data, a more conclusive statement about the individual role of these genes 
in the pathology of metabolic syndrome may provide influential insight into the etiology and 
pathology of this increasingly prevalent disorder. 
 Overall, the importance of this study was to find novel genes that relate to the pathologic 
effects of metabolic syndrome.  Although preliminary PCR data was only able to verify the 
trends in gene expression for two of the genes, these genes could be investigated even further 
and eventually become the target of a new therapy or drug for metabolic syndrome or one of its 
debilitating complications.  This study serves as preliminary research into possible genes 








































qw1<- qnorm_w[rank(z1)]; qw2<- qnorm_w[rank(z2)]; qw3<- qnorm_w[rank(z3)] 
qnorm_m<-(1/3)*(sort(z4)+sort(z5)+sort(z6)) 





























# To verify that 90th percentile is computed correctly 







#get mean for each gene in mutant arrays 
mean.m<-apply(m,1,mean) 
#get mean for each gene in wild-type arrays 
mean.w<-apply(w,1,mean) 
 
#find difference between means for each gene 
diff1<-mean.m-mean.w 
 
#define how many mutant arrays 
n.m=3 
#define how many wild-type arrays 
n.w=3 
 




#get std. dev. for each gene in wild-type arrays 
s.w<-apply(w,1,sd) 
 
a<-(1/n.m + 1/n.w)/(n.m+n.w-2) 
 
#gene specific scatter is computed 
si1<- sqrt( a*((n.m-1)*s.m^2+(n.w-1)*s.w^2)) 
 
#gene relative difference between group means is computed (SAM method) 
di1 <- diff1/(si1+s01) 
 
#Weight for effect size meta-analysis 




diff,di1, si1, s1) 
 























qw1<- qnorm_w[rank(z1)]; qw2<- qnorm_w[rank(z2)]; qw3<- qnorm_w[rank(z3)] 
qnorm_m<-(1/3)*(sort(z4)+sort(z5)+sort(z6)) 

















a<-(1/n.m + 1/n.w)/(n.m+n.w-2) 
 
#gene specific scatter is computed 
si2<- sqrt( a*((n.m-1)*s.m^2+(n.w-1)*s.w^2)) 
 





# To verify that 90th percentile is computed correctly 
length(which (se11 > s02)) 
 
 
#gene relative difference between group means is computed (SAM method) 
di2 <- diff2/(si2+s02) 
 
#Weight for effect size meta-analysis 
s2<-(1/n.m + 1/n.w + (di2)^2/(2*(n.m+n.w))) 
 
































#get mean for each gene in mutant arrays 
mean.m<-apply(m,1,mean) 
#get mean for each gene in wild-type arrays 
mean.w<-apply(w,1,mean) 
 
#find difference between means for each gene 
diff5<-mean.m-mean.w 
 
#get std. dev. for each gene in mutant arrays 
s.m<-apply(m,1,sd) 
#get std. dev. for each gene in wild-type arrays 
s.w<-apply(w,1,sd) 
 
#define how many mutant arrays 
n.m=6 
#define how many wild-type arrays 
n.w=4 
 





# To verify that 90th percentile is computed correctly 
length(which (se11 > s05)) 
 
a<-(1/n.m + 1/n.w)/(n.m+n.w-2) 
 
#gene specific scatter is computed 
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si5<- sqrt( a*((n.m-1)*s.m^2+(n.w-1)*s.w^2)) 
 
#gene relative difference between group menas is computed (SAM method) 





#Weight for effect size meta-analysis 
s5<-(1/n.m + 1/n.w + (di5)^2/(2*(n.m+n.w))) 
 
indiv5<-data.frame(Gene.Symbol, Gene.ID,col3,col4,col5,col6,col7,col8,col9,col10,col11,col12, 









#write this data file into an Excel file for easy viewing 





#Computing an average combined study effect size (meta-analysis effect size) 
mu <- (di1*(1/s1) + di2*(1/s2)+di5*(1/s5))/(1/s1+1/s2+1/s5) 
#Computing variance for the average combined study effect size 
vmu <- (1/s1+1/s2+1/s5)/(1/s1+1/s2+1/s5)**2 
#Computing meta z score 
z0 <- mu/sqrt(vmu) 
 














plot(x <- sort(z0), type="s", title="Distribution of Meta-Zs") 
 
################################################ 
#Different effect size standard error 
################################################ 
  
s11 = (si1+s01)**2 
s22 = (si2+s02)**2 
s55 = (si5+s05)**2 
#Computing an average combined study effect size (meta-analysis effect size) 
mu.n <- (di1*(1/s11) + di2*(1/s22)+di5*(1/s55))/(1/s11+1/s22+1/s55) 
#Computing variance for the average combined study effect size 
vmu.n <- (1/s11+1/s22+1/s55)/(1/s11+1/s22+1/s55)**2 
#Computing meta z score 
z0.n <- mu.n/sqrt(vmu.n) 
 















B <- 100 
 
 
for(j in 1:B) 
{ 
x <- zzn1[,sample (ncol(zzn1))] 
w <- x[, 1:3] 










a<-(1/n.m + 1/n.w)/(n.m+n.w-2) 
#gene specific scatter is computed 






size1 <- ((mean.m-mean.w)/(sep+s01)) 




x <- zzn2[,sample (ncol(zzn2))] 
w <- x[, 1:3] 








a<-(1/n.m + 1/n.w)/(n.m+n.w-2) 
#gene specific scatter is computed 






size2 <- ((mean.m-mean.w)/(sep+s0)) 
s2<- (1/n.m + 1/n.w + size2^2/(2*n.m+2*n.w)) 
 
################################################################ 
x <- zzn5[,sample (ncol(zzn5))] 
w <- x[, 1:4] 








a<-(1/n.m + 1/n.w)/(n.m+n.w-2) 
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#gene specific scatter is computed 






size5 <- ((mean.m-mean.w)/(sep+s0)) 




all <- data.frame(Gene.ID, Gene.Symbol, size1,s1, size2, s2,size5, s5) 
 
for(i in 1:n) 
{ 
     w1[i] <- sum(1/all[i,4]+ 1/all[i,6] + 1/all[i,8] ) 
     muF[i]<- (sum(1/all[i,4]*all[i,3]+ 1/all[i,6]*all[i,5] + 1/all[i,8]*all[i,7] ))/w1[i] 
     muVar[i] <- w1[i]/(w1[i])^2 
 b[i]<-muF[i]/sqrt(muVar[i])  
} 





































for(i in 1:n){ 
count[i]<-0 
for(j in 1:B){ 
if (abs(z0[i]) > abs(perm.Z[i,j])) 
count[i] = count[i]+1 
} 
} 




for(j in 1:B) 
{ 










































































ENCODES a protein that exhibits actin binding 
(ortholog) AND  transcription coactivator activity 
(ortholog) AND  INVOLVED IN positive regulation of 
Rho protein signal transduction (ortholog) AND  positive 
regulation of sequence-specific DNA binding 
transcription factor activity (ortholog) AND  positive 
regulation of transcription from RNA polymerase II 
promoter (ortholog) AND  FOUND IN sarcomere AND  
actin cytoskeleton (ortholog) AND  myofibril (ortholog) 
AND  INTERACTS WITH C60 fullerene AND  all-











ENCODES a protein that exhibits AMP deaminase 
activity AND  INVOLVED IN AMP catabolic process 
(inferred) AND  IMP biosynthetic process (inferred) 
AND  IMP salvage (inferred) AND  PARTICIPATES IN 
purine metabolic pathway AND  ASSOCIATED WITH 
Heart Diseases (ortholog) AND  Muscular Diseases 
(ortholog) AND  Stroke (ortholog) AND  INTERACTS 









ENCODES a protein that exhibits fatty acid binding 
(ortholog) AND  lipase inhibitor activity (ortholog) AND  
phospholipase inhibitor activity (ortholog) AND  
INVOLVED IN regulation of lipid transport AND  
cholesterol efflux (ortholog) AND  cholesterol metabolic 
process (ortholog) AND  PARTICIPATES IN altered 
lipoprotein metabolic pathway AND  lipoprotein 
metabolic pathway AND  ASSOCIATED WITH 
Alzheimer Disease (ortholog) AND  Carcinoma  
Pancreatic Ductal (ortholog) AND  Diabetes Mellitus  
Type 2 (ortholog) AND  FOUND IN high-density 
lipoprotein particle AND  very-low-density lipoprotein 
particle AND  endoplasmic reticulum (ortholog) AND  
INTERACTS WITH 17alpha-ethynylestradiol AND  3-













INVOLVED IN signal transduction (inferred) AND  
FOUND IN intracellular (inferred) AND  INTERACTS 
WITH sodium dichromate AND  (-)-epigallocatechin 3-









ENCODES a protein that exhibits catalytic activity 











process (inferred) AND  INTERACTS WITH 2 3 7 8-
tetrachlorodibenzodioxine (ortholog) AND  paracetamol 








ENCODES a protein that exhibits protein 
homodimerization activity (ortholog) AND  INVOLVED 
IN aging AND  brain development AND  response to 
glucocorticoid stimulus AND  PARTICIPATES IN 
Staphylococcus aureus infection pathway AND  
Trypanosoma cruzi infection pathway AND  coagulation 
cascade pathway AND  ASSOCIATED WITH Ocular 
Hypertension AND  Retrograde Degeneration AND  
Spinal Cord Injuries AND  FOUND IN complement 
component C1 complex AND  INTERACTS WITH 1 3-














INVOLVED IN complement activation  classical 
pathway (inferred) AND  innate immune response 
(inferred) AND  PARTICIPATES IN forkhead class A 
signaling pathway AND  coagulation cascade pathway 
AND  complement system pathway AND  FOUND IN 
extracellular region (inferred) AND  INTERACTS 
WITH 2 3 7 8-tetrachlorodibenzodioxine AND  3H-1 2-











ENCODES a protein that exhibits scaffold protein 
binding AND  INVOLVED IN germ cell programmed 
cell death (ortholog) AND  FOUND IN neuron 
projection AND  neuronal cell body AND  protein 
complex AND  INTERACTS WITH 1 1 1-trichloro-2 2-
bis(4-hydroxyphenyl)ethane AND  1 2 4-












ENCODES a protein that exhibits fibronectin binding 
(ortholog) AND  glycosaminoglycan binding (ortholog) 
AND  heparin binding (ortholog) AND  INVOLVED IN 
extracellular matrix organization (ortholog) AND  
positive regulation of cell-substrate adhesion (ortholog) 
AND  FOUND IN basement membrane (ortholog) AND  
extracellular matrix (ortholog) AND  interstitial matrix 
(ortholog) AND  INTERACTS WITH diuron AND  











ENCODES a protein that exhibits CCR2 chemokine 
receptor binding AND  chemokine activity AND  heparin 
binding AND  INVOLVED IN aging AND  cellular 
calcium ion homeostasis AND  chemokine-mediated 
signaling pathway AND  PARTICIPATES IN 
angiotensin II signaling pathway AND  vascular 
endothelial growth factor signaling pathway AND  
granulocyte-macrophage colony-stimulating factor 








Lung Injury AND  Anti-Glomerular Basement 
Membrane Disease AND  Aortic Aneurysm  Abdominal 
AND  FOUND IN cytoplasm AND  extracellular space 
AND  neuronal cell body AND  INTERACTS WITH ( )-






ENCODES a protein that exhibits chemokine activity 
AND  cytokine activity (ortholog) AND  INVOLVED IN 
chemokinesis AND  PARTICIPATES IN chemokine 
mediated signaling pathway AND  cytokine mediated 
signaling pathway AND  rheumatoid arthritis pathway 
AND  FOUND IN extracellular space (inferred) AND  
INTERACTS WITH 1 2 4-trimethylbenzene AND  2-







Ccna2 cyclin A2 ENCODES a protein that exhibits protein kinase binding 
(ortholog) AND  INVOLVED IN organ regeneration 
AND  positive regulation of fibroblast proliferation AND  
response to estradiol stimulus AND  PARTICIPATES IN 
p53 signaling pathway AND  cell cycle pathway  mitotic 
AND  ASSOCIATED WITH Carcinoma  Embryonal 
(ortholog) AND  Heart Failure (ortholog) AND  
Mammary Neoplasms  Experimental (ortholog) AND  
FOUND IN cytoplasm (ortholog) AND  female 
pronucleus (ortholog) AND  male pronucleus (ortholog) 
AND  INTERACTS WITH 2 3 7 8-
tetrachlorodibenzodioxine AND  2-acetamidofluorene 







FOUND IN centrosome (ortholog) AND  INTERACTS 










INVOLVED IN mitotic cytokinesis (ortholog) AND  
negative regulation of microtubule depolymerization 
(ortholog) AND  positive regulation of transcription from 
RNA polymerase II promoter (ortholog) AND  FOUND 
IN centrosome (ortholog) AND  cytoplasm (ortholog) 
AND  cytoplasmic microtubule (ortholog) AND  
INTERACTS WITH 2-amino-2-deoxy-D-glucopyranose 









ENCODES a protein that exhibits ciliary neurotrophic 
factor receptor binding (ortholog) AND  cytokine activity 
(ortholog) AND  protein heterodimerization activity 
(ortholog) AND  INVOLVED IN B cell differentiation 
(ortholog) AND  JAK-STAT cascade (ortholog) AND  
cell surface receptor signaling pathway (ortholog) AND  
PARTICIPATES IN Jak-Stat signaling pathway AND  
cytokine mediated signaling pathway AND  
ASSOCIATED WITH Cold-Induced Sweating 






CLCF1 complex (ortholog) AND  CRLF-CLCF1 
complex (ortholog) AND  extracellular region (ortholog) 
AND  INTERACTS WITH 2 4-dinitrotoluene AND  2 6-
dinitrotoluene AND  C60 fullerene 
Clu clusterin ENCODES a protein that exhibits ATPase activity 
(ortholog) AND  misfolded protein binding (ortholog) 
AND  ubiquitin protein ligase binding (ortholog) AND  
INVOLVED IN cellular response to growth factor 
stimulus AND  endocrine pancreas development AND  
negative regulation of apoptotic process AND  
ASSOCIATED WITH Brain Ischemia AND  Ischemia 
AND  Arteriosclerosis (ortholog) AND  FOUND IN 
aggresome AND  growth cone AND  neuron projection 
AND  INTERACTS WITH 1-naphthyl isothiocyanate 













FOUND IN integral to membrane (inferred) AND  
INTERACTS WITH cisplatin AND  2 3 7 8-








INVOLVED IN camera-type eye morphogenesis 
(ortholog) AND  epithelial cell proliferation (ortholog) 
AND  positive regulation of cell-substrate adhesion 
(ortholog) AND  PARTICIPATES IN syndecan signaling 
pathway AND  FOUND IN extracellular matrix 
(ortholog) AND  INTERACTS WITH 2-amino-2-deoxy-









ENCODES a protein that exhibits tRNA binding 
(ortholog) AND  INVOLVED IN tRNA thio-
modification (ortholog) AND  tRNA wobble uridine 
modification (ortholog) AND  FOUND IN cytosol 
(ortholog) AND  mitochondrion (ortholog) AND  
INTERACTS WITH 2 3 7 8-tetrachlorodibenzodioxine 
(ortholog) AND  benzo[a]pyrene (ortholog) AND  










ENCODES a protein that exhibits chemokine activity 
AND  INVOLVED IN cellular response to heat AND  
immune response AND  negative regulation of 
angiogenesis AND  PARTICIPATES IN Retinoic acid-
inducible gene (RIG) I-like receptor signaling pathway 
AND  Toll-like receptor signaling pathway AND  
chemokine mediated signaling pathway AND  
ASSOCIATED WITH Brain Ischemia AND  
Bronchiolitis  Viral AND  Diabetes Mellitus  Type 1 








of plasma membrane (ortholog) AND  extracellular 
region (ortholog) AND  INTERACTS WITH 2 3 7 8-
tetrachlorodibenzodioxine AND  2 4 6-trinitrotoluene 









ENCODES a protein that exhibits testosterone 16-alpha-
hydroxylase activity AND  caffeine oxidase activity 
(ortholog) AND  drug binding (ortholog) AND  
INVOLVED IN cellular amide metabolic process 
(ortholog) AND  drug catabolic process (ortholog) AND  
drug metabolic process (ortholog) AND  
PARTICIPATES IN arachidonic acid metabolic pathway 
AND  linoleic acid metabolic pathway AND  phase I 
biotransformation pathway via cytochrome P450 AND  
ASSOCIATED WITH Depressive Disorder AND  
Hypertension AND  Kidney Failure  Chronic AND  
FOUND IN intracellular membrane-bounded organelle 
(ortholog) AND  INTERACTS WITH 1 1-dichloroethene 









ENCODES a protein that exhibits protein kinase activity 
AND  INVOLVED IN protein phosphorylation AND  
INTERACTS WITH C60 fullerene AND  N-













INVOLVED IN maintenance of mitotic sister chromatid 
cohesion (ortholog) AND  post-translational protein 
acetylation (ortholog) AND  regulation of DNA 
replication (ortholog) AND  FOUND IN chromatin 
(ortholog) AND  chromosome  centromeric region 
(ortholog) AND  nucleoplasm (ortholog) AND  












ENCODES a protein that exhibits protein C-terminus 
binding AND  receptor binding AND  FOUND IN 
intracellular membrane-bounded organelle (ortholog) 
AND  INTERACTS WITH 2 3 7 8-







INTERACTS WITH 17alpha-ethynylestradiol AND  







ENCODES a protein that exhibits immunoglobulin 
receptor binding (ortholog) AND  non-membrane 
spanning protein tyrosine kinase activity (ortholog) AND  
phosphatidylinositol binding (ortholog) AND  
INVOLVED IN peptidyl-tyrosine phosphorylation 
(ortholog) AND  positive regulation of actin cytoskeleton 
reorganization (ortholog) AND  positive regulation of 
microtubule polymerization (ortholog) AND  
PARTICIPATES IN interleukin-4 signaling pathway 
AND  vascular endothelial growth factor signaling 






cytoplasmic vesicle (ortholog) AND  extrinsic to internal 
side of plasma membrane (ortholog) AND  INTERACTS 
WITH C60 fullerene AND  2 3 7 8-
tetrachlorodibenzodioxine (ortholog) AND  N-methyl-N'-
nitro-N-nitrosoguanidine (ortholog) 
Fetub fetuin B ENCODES a protein that exhibits metalloendopeptidase 
inhibitor activity (ortholog) AND  INVOLVED IN 
binding of sperm to zona pellucida (ortholog) AND  
negative regulation of endopeptidase activity (ortholog) 
AND  single fertilization (ortholog) AND  FOUND IN 
extracellular space (inferred) AND  INTERACTS WITH 









FOUND IN extracellular region (inferred) AND  
INTERACTS WITH N-acetyl-L-cysteine AND  N-






Grem1 gremlin 1 ENCODES a protein that exhibits protein tyrosine kinase 
activator activity (ortholog) AND  receptor agonist 
activity (ortholog) AND  vascular endothelial growth 
factor receptor 2 binding (ortholog) AND  INVOLVED 
IN apoptotic process AND  negative regulation of cell 
growth AND  negative regulation of leukocyte 
chemotaxis AND  PARTICIPATES IN Bone 
morphogenetic proteins signaling pathway AND  
FOUND IN cell surface AND  extracellular space AND  
INTERACTS WITH 1 1 1-trichloro-2 2-bis(4-
hydroxyphenyl)ethane AND  1 2 4-trimethylbenzene 










ENCODES a protein that exhibits DNA binding 
(ortholog) AND  sequence-specific DNA binding RNA 
polymerase II transcription factor activity (ortholog) 
AND  INVOLVED IN central nervous system 
development (ortholog) AND  cochlea morphogenesis 
(ortholog) AND  ectoderm development (ortholog) AND  
FOUND IN nucleus (ortholog) AND  INTERACTS 
WITH diuron AND  2 3 7 8-tetrachlorodibenzodioxine 










INVOLVED IN phagocytosis  engulfment AND  
response to antibiotic AND  response to drug AND  
ASSOCIATED WITH Acute Kidney Injury AND  
Cardio-Renal Syndrome AND  Colitis AND  FOUND IN 
apical plasma membrane AND  cell surface AND  
cytoplasm AND  INTERACTS WITH 1-naphthyl 











ENCODES a protein that exhibits coreceptor activity 
(ortholog) AND  INVOLVED IN BMP signaling 
pathway (ortholog) AND  iron ion homeostasis 
(ortholog) AND  positive regulation of transcription from 








PARTICIPATES IN Bone morphogenetic proteins 
signaling pathway AND  ASSOCIATED WITH 
Hemochromatosis (ortholog) AND  FOUND IN 
basolateral plasma membrane AND  cell surface 
(ortholog) AND  extracellular space (ortholog) AND  
INTERACTS WITH 2 3 7 8-tetrachlorodibenzodioxine 











ENCODES a protein that exhibits 3-beta-hydroxy-delta5-
steroid dehydrogenase activity; steroid delta-isomerase 
activity; INVOLVED IN androgen biosynthetic process; 
C21-steroid hormone biosynthetic process; hippocampus 
development; PARTICIPATES IN cortisol biosynthetic 
pathway; estradiol biosynthetic pathway; steroid 
hormone biosynthetic pathway; ASSOCIATED WITH 
Hyperprolactinemia; Hypertension; FOUND IN 
mitochondrial inner membrane (ortholog); mitochondrial 











ENCODES a protein that exhibits mRNA binding 
(ortholog) AND  FOUND IN cytoplasm (ortholog) AND  
nucleus (ortholog) AND  ribonucleoprotein complex 
(ortholog) AND  INTERACTS WITH L-methionine 













ENCODES a protein that exhibits ion channel binding 
AND  potassium channel regulator activity AND  
sequence-specific DNA binding AND  INVOLVED IN 
intracellular protein transport AND  behavioral response 
to pain (ortholog) AND  negative regulation of 
transcription from RNA polymerase II promoter 
(ortholog) AND  PARTICIPATES IN calcium/calcium-
mediated signaling pathway AND  FOUND IN axon 
AND  axon terminus AND  dendrite AND  INTERACTS 
WITH ammonium chloride AND  tetrachloromethane 










ENCODES a protein that exhibits serine-type 
endopeptidase activity (inferred) AND  INVOLVED IN 
positive regulation of vasoconstriction AND  
INTERACTS WITH cyclosporin A AND  sirolimus 













INVOLVED IN chromosome segregation (ortholog) 
AND  mitotic anaphase (ortholog) AND  mitotic sister 
chromatid segregation (ortholog) AND  FOUND IN 
kinetochore (ortholog) AND  microtubule plus end 
(ortholog) AND  mitotic spindle (ortholog) AND  
INTERACTS WITH 17alpha-ethynylestradiol AND  N-








INVOLVED IN mitotic cell cycle checkpoint (ortholog) 










AND  spindle pole (ortholog) AND  INTERACTS WITH 
cefaloridine AND  (-)-epigallocatechin 3-gallate 
(ortholog) AND  2 3 7 8-tetrachlorodibenzodioxine 
(ortholog) 
Krt25 keratin 25 ENCODES a protein that exhibits structural molecule 
activity (inferred) AND  INVOLVED IN hair follicle 
morphogenesis (ortholog) AND  intermediate filament 
organization (ortholog) AND  FOUND IN cytoplasm 
(inferred) AND  intermediate filament (inferred) AND  
INTERACTS WITH L-methionine (ortholog) AND  














ENCODES a protein that exhibits scavenger receptor 
activity (inferred) AND  INVOLVED IN cell adhesion 
(inferred) AND  FOUND IN extracellular matrix 
(ortholog) AND  extracellular vesicular exosome 
(ortholog) AND  INTERACTS WITH 17alpha-




































INTERACTS WITH fonofos (ortholog); parathion 













INTERACTS WITH arsenic atom (ortholog) AND  





















ENCODES a protein that exhibits calcium ion binding 
(inferred) AND  growth factor binding (inferred) AND  
heparin binding (inferred) AND  ASSOCIATED WITH 
Glaucoma 3  Primary Congenital  D (ortholog) AND  
Tooth Agenesis  Selective  6 (ortholog) AND  FOUND 
IN extracellular matrix (ortholog) AND  extracellular 
space (ortholog) AND  extracellular vesicular exosome 
(ortholog) AND  INTERACTS WITH 17alpha-









Lum lumican ENCODES a protein that exhibits collagen binding 
(ortholog) AND  INVOLVED IN cartilage development 
AND  response to growth factor stimulus AND  response 
to organic cyclic compound AND  ASSOCIATED WITH 
Fibrosis AND  Myocardial Reperfusion Injury AND  
Spinal Cord Injuries AND  FOUND IN proteinaceous 
extracellular matrix AND  extracellular matrix (ortholog) 
AND  extracellular space (ortholog) AND  INTERACTS 
WITH 17alpha-ethynylestradiol AND  N-ethyl-N-











INVOLVED IN extracellular fibril organization 
(ortholog) AND  PARTICIPATES IN Notch signaling 
pathway AND  FOUND IN extracellular matrix 
(ortholog) AND  INTERACTS WITH dexamethasone 












ENCODES a protein that exhibits calcium ion binding 
AND  methylated-DNA-[protein]-cysteine S-
methyltransferase activity AND  methyltransferase 
activity (ortholog) AND  INVOLVED IN DNA 
dealkylation involved in DNA repair AND  cellular 
response to ionizing radiation AND  cellular response to 
organic cyclic compound AND  ASSOCIATED WITH 
Colonic Neoplasms AND  Melanoma AND  Bile Duct 
Neoplasms (ortholog) AND  FOUND IN nucleus AND  
INTERACTS WITH ( )-pilocarpine AND  2 3 7 8-












al cysts 1 
ENCODES a protein that exhibits protein transporter 
activity AND  protein complex binding (ortholog) AND  
INVOLVED IN caveolin-mediated endocytosis AND  
cellular response to cholesterol AND  protein transport 
AND  ASSOCIATED WITH Megalencephalic 
leukoencephalopathy with subcortical cysts (ortholog) 
AND  FOUND IN caveola AND  clathrin-coated vesicle 
AND  cytoplasmic vesicle AND  INTERACTS WITH 2 
3 7 8-tetrachlorodibenzodioxine AND  2 4-dinitrotoluene 











ENCODES a protein that exhibits G-protein coupled 
receptor activity (inferred) AND  FOUND IN integral to 
membrane (inferred) AND  plasma membrane (inferred) 










ENCODES a protein that exhibits heparin binding AND  
identical protein binding AND  protein kinase C binding 
AND  INVOLVED IN induction of apoptosis AND  
positive regulation of ossification AND  protein 
homotrimerization AND  ASSOCIATED WITH 
abnormal craniofacial bone morphology AND  
ASSOCIATED WITH Craniosynostoses AND  FOUND 
IN cytoplasm AND  extracellular space AND  nuclear 
















FOUND IN mitochondrion (ortholog) AND  
INTERACTS WITH 17alpha-ethynylestradiol AND  2-










INTERACTS WITH 2 3 7 8-tetrachlorodibenzodioxine 












d factor 1 
ENCODES a protein that exhibits leucine zipper domain 
binding (ortholog) AND  transcription coactivator 
activity (ortholog) AND  INVOLVED IN chromosome 
segregation (ortholog) AND  FOUND IN MIS12/MIND 
type complex (ortholog) AND  INTERACTS WITH 











INTERACTS WITH N-nitrosodiethylamine AND  all-











ENCODES a protein that exhibits identical protein 
binding (ortholog) AND  protein kinase binding 
(ortholog) AND  INVOLVED IN cytokinesis (ortholog) 
AND  FOUND IN cytoplasm (ortholog) AND  
microtubule cytoskeleton (ortholog) AND  nucleus 
(ortholog) AND  INTERACTS WITH 2-
acetamidofluorene AND  2-amino-2-deoxy-D-











ENCODES a protein that exhibits hormone activity 
(inferred) AND  FOUND IN extracellular region 
(inferred) AND  INTERACTS WITH ammonium 













ENCODES a protein that exhibits threonine-type 
endopeptidase activity (inferred) AND  INVOLVED IN 
antigen processing and presentation (ortholog) AND  
PARTICIPATES IN ubiquitin/proteasome degradation 
pathway AND  ASSOCIATED WITH Colorectal 
Neoplasms (ortholog) AND  Diabetes Mellitus  Type 1 
(ortholog) AND  Esophageal Neoplasms (ortholog) AND  
FOUND IN proteasome core complex (ortholog) AND  
spermatoproteasome complex (ortholog) AND  
INTERACTS WITH 1 3-dinitrobenzene AND  17alpha-









ENCODES a protein that exhibits lipid binding AND  
oxidoreductase activity  acting on single donors with 











atoms of oxygen AND  enzyme binding (ortholog) AND  
INVOLVED IN angiogenesis AND  bone mineralization 
AND  cellular response to ATP AND  PARTICIPATES 
IN sphingosine 1-phosphate signaling pathway AND  
Leishmania infection pathway AND  arachidonic acid 
metabolic pathway AND  ASSOCIATED WITH Acute 
Kidney Injury AND  Acute Lung Injury AND  
Adenocarcinoma AND  FOUND IN caveola AND  
cytoplasm AND  protein complex AND  INTERACTS 
WITH (-)-epigallocatechin 3-gallate AND  (R)-lipoic 






ENCODES a protein that exhibits hormone activity AND  
peptide hormone receptor binding (ortholog) AND  
INVOLVED IN adenylate cyclase-activating G-protein 
coupled receptor signaling pathway AND  endochondral 
ossification (ortholog) AND  endoderm development 
(ortholog) AND  PARTICIPATES IN Hedgehog 
signaling pathway AND  ASSOCIATED WITH 
BRACHYDACTYLY  TYPE E2 (ortholog) AND  
Hypercalcemia (ortholog) AND  FOUND IN Golgi 
apparatus (ortholog) AND  cytoplasm (ortholog) AND  
intracellular (ortholog) AND  INTERACTS WITH L-















ENCODES a protein that exhibits protein tyrosine 
phosphatase activity (inferred) AND  INVOLVED IN 
axonogenesis (ortholog) AND  ASSOCIATED WITH 
Helicobacter Infections (ortholog) AND  FOUND IN 
perineuronal net (ortholog) AND  proteinaceous 
extracellular matrix (ortholog) AND  INTERACTS 












ENCODES a protein that exhibits GTP binding (inferred) 
AND  INVOLVED IN protein transport (inferred) AND  
small GTPase mediated signal transduction (inferred) 
AND  FOUND IN plasma membrane (inferred) AND  
INTERACTS WITH C60 fullerene AND  rosiglitazone 










ENCODES a protein that exhibits nucleic acid binding 










ENCODES a protein that exhibits protein 
heterodimerization activity AND  retinol binding AND  
retinol transporter activity AND  INVOLVED IN 
response to ethanol AND  retinol metabolic process AND  
retinol transport AND  PARTICIPATES IN retinoic acid 
metabolic pathway AND  ASSOCIATED WITH 
Diabetes Mellitus  Type 2 AND  Obesity AND  








space AND  protein complex AND  INTERACTS WITH 
17alpha-ethynylestradiol AND  2 3 7 8-




INTERACTS WITH 2 3 7 8-tetrachlorodibenzodioxine 













INTERACTS WITH dibutyl phthalate AND  furan AND  












ENCODES a protein that exhibits hydroxyisourate 
hydrolase activity (inferred) AND  INVOLVED IN 
purine nucleobase metabolic process (inferred) AND  
transport (inferred) AND  PARTICIPATES IN purine 
metabolic pathway AND  INTERACTS WITH 2 3 7 8-













ENCODES a protein that exhibits kinase binding 
(inferred) AND  INVOLVED IN axonogenesis AND  
FOUND IN axon (inferred) AND  cytosol (inferred) 
AND  INTERACTS WITH 2 3 7 8-
tetrachlorodibenzodioxine AND  (-)-epigallocatechin 3-

























ASSOCIATED WITH Tumoral Calcinosis  
Normophosphatemic  Familial (ortholog) AND  FOUND 
IN cytoplasm (ortholog) AND  intracellular membrane-
bounded organelle (ortholog) AND  INTERACTS WITH 
chloroprene AND  diethylstilbestrol AND  (-)-











ENCODES a protein that exhibits endopeptidase 
inhibitor activity (inferred) AND  FOUND IN 
extracellular space (inferred) AND  INTERACTS WITH 













ENCODES a protein that exhibits protein complex 
binding AND  syntaxin-1 binding AND  ubiquitin-
protein ligase activity AND  INVOLVED IN ubiquitin-
dependent protein catabolic process AND  histone H2B 
ubiquitination (ortholog) AND  histone 
monoubiquitination (ortholog) AND  FOUND IN neuron 
projection AND  protein complex AND  HULC complex 
(ortholog) AND  INTERACTS WITH 2 3 7 8-















ENCODES a protein that exhibits Lys63-specific 
deubiquitinase activity (ortholog); proline-rich region 
binding (ortholog); protein kinase binding (ortholog); 
INVOLVED IN necroptotic process (ortholog); negative 
regulation of canonical Wnt signaling pathway 
(ortholog); negative regulation of NF-kappaB import into 
nucleus (ortholog); PARTICIPATES IN nuclear factor 
kappa B signaling pathway; tumor necrosis factor 
mediated signaling pathway; Retinoic acid-inducible 
gene (RIG) I-like receptor signaling pathway; 
ASSOCIATED WITH Familial cylindromatosis 
(ortholog); Skin Neoplasms (ortholog); 
Trichoepithelioma multiple familial (ortholog); FOUND 
IN centrosome (ortholog); cytoplasmic microtubule 
(ortholog); cytosol (ortholog); INTERACTS WITH 










ENCODES a protein that exhibits ribonucleoside-
diphosphate reductase activity  thioredoxin disulfide as 
acceptor (ortholog) AND  INVOLVED IN mitotic cell 
cycle AND  positive regulation of cell proliferation AND  
pyrimidine nucleobase metabolic process AND  
PARTICIPATES IN glutathione metabolic pathway 
AND  p53 signaling pathway AND  purine metabolic 
pathway AND  ASSOCIATED WITH Endometrial 
Neoplasms AND  Urinary Bladder Neoplasms AND  
Breast Neoplasms (ortholog) AND  FOUND IN nuclear 
envelope AND  INTERACTS WITH 17alpha-












ENCODES a protein that exhibits peptide antigen 
binding (ortholog) AND  INVOLVED IN T-helper 1 
type immune response (ortholog) AND  antigen 
processing and presentation of exogenous peptide antigen 
via MHC class II (ortholog) AND  detection of bacterium 
(ortholog) AND  PARTICIPATES IN interleukin-12 
signaling pathway AND  Leishmania infection pathway 
AND  Mycobacterium tuberculosis infection pathway 
AND  ASSOCIATED WITH Addison Disease (ortholog) 
AND  Alzheimer Disease (ortholog) AND  Anti-
Glomerular Basement Membrane Disease (ortholog) 
AND  FOUND IN external side of plasma membrane 
(ortholog) AND  late endosome membrane (ortholog) 
AND  lysosomal membrane (ortholog) AND  
INTERACTS WITH 3H-1 2-dithiole-3-thione AND  N-










INVOLVED IN centriole replication (ortholog) AND  
centrosome duplication (ortholog) AND  FOUND IN 
centriole (ortholog) AND  centrosome (ortholog) AND  










(ortholog) AND  2 3 7 8-tetrachlorodibenzodioxine 
(ortholog) AND  4-hydroxynon-2-enal (ortholog) 
Scg2 secretogr
anin II 
ENCODES a protein that exhibits chemoattractant 
activity (ortholog) AND  cytokine activity (ortholog) 
AND  INVOLVED IN MAPK cascade (ortholog) AND  
angiogenesis (ortholog) AND  cellular component 
movement (ortholog) AND  FOUND IN secretory 
granule AND  extracellular space (ortholog) AND  
INTERACTS WITH (S)-nicotine AND  1 3-












FOUND IN extracellular region (inferred) AND  
INTERACTS WITH 17alpha-ethynylestradiol AND  















ENCODES a protein that exhibits heparin binding AND  
serine-type endopeptidase inhibitor activity AND  
protease binding (ortholog) AND  INVOLVED IN 
negative regulation of inflammatory response AND  
response to nutrient AND  PARTICIPATES IN glypican 
signaling pathway AND  coagulation cascade pathway 
AND  complement system pathway AND  
ASSOCIATED WITH Endotoxemia AND  Inflammation 
AND  Jaundice AND  FOUND IN extracellular space 
AND  INTERACTS WITH 2 4-dinitrotoluene AND  2 6-










ENCODES a protein that exhibits proton-dependent 
oligopeptide secondary active transmembrane transporter 
activity (inferred) AND  symporter activity (inferred) 
AND  INVOLVED IN protein transport (inferred) AND  
FOUND IN lysosomal membrane AND  INTERACTS 












ENCODES a protein that exhibits SNARE binding AND  
myosin binding AND  protein N-terminus binding AND  
INVOLVED IN axonogenesis AND  calcium ion-
dependent exocytosis of neurotransmitter AND  
endosomal transport AND  PARTICIPATES IN insulin 
secretion pathway AND  ASSOCIATED WITH Down 
Syndrome (ortholog) AND  FOUND IN SNARE 
complex AND  actin cytoskeleton AND  axon AND  
INTERACTS WITH C60 fullerene AND  ammonium 











ENCODES a protein that exhibits growth hormone 
receptor binding (ortholog) AND  insulin-like growth 
factor receptor binding (ortholog) AND  INVOLVED IN 
aging AND  response to peptide hormone stimulus AND  
cellular response to hormone stimulus (ortholog) AND  
PARTICIPATES IN Jak-Stat signaling pathway AND  
interleukin-2 signaling pathwayinsulin signaling pathway 








Injuries AND  Breast Neoplasms (ortholog) AND  
INTERACTS WITH 1 3-dinitrobenzene AND  3H-1 2-
dithiole-3-thione AND  ammonium chloride 







ENCODES a protein that exhibits ATP binding (inferred) 
AND  protein serine/threonine kinase activity (inferred) 
AND  INTERACTS WITH 17beta-estradiol AND  









ENCODES a protein that exhibits identical protein 
binding (ortholog) AND  protein heterodimerization 
activity (ortholog) AND  protein homodimerization 
activity (ortholog) AND  INVOLVED IN response to 
stress AND  FOUND IN cell junction (inferred) AND  
integral to membrane (inferred) AND  synaptic vesicle 
membrane (inferred) AND  INTERACTS WITH 
ammonium chloride AND  bis(2-ethylhexyl) phthalate 














ENCODES a protein that exhibits ADP binding AND  
ATP binding AND  ATPase activity AND  INVOLVED 
IN ATP catabolic process AND  peptide transport AND  
protection from natural killer cell mediated cytotoxicity 
AND  PARTICIPATES IN antigen processing and 
presentation pathway AND  phagocytosis pathway AND  
primary immunodeficiency disease pathway AND  
ASSOCIATED WITH Alveolitis  Extrinsic Allergic 
(ortholog) AND  Arthritis  Reactive (ortholog) AND  
Asthma (ortholog) AND  FOUND IN TAP complex 
AND  intracellular membrane-bounded organelle AND  
integral to endoplasmic reticulum membrane (ortholog) 
AND  INTERACTS WITH 2 6-dinitrotoluene AND  2-












ENCODES a protein that exhibits protease binding AND  
metalloendopeptidase inhibitor activity (ortholog) AND  
INVOLVED IN aging AND  cartilage development AND  
cell activation AND  PARTICIPATES IN interleukin-6 
signaling pathway AND  ASSOCIATED WITH Brain 
Injuries AND  Cholestasis AND  Diabetes Mellitus  
Experimental AND  FOUND IN extracellular matrix 
AND  basement membrane (ortholog) AND  
proteinaceous extracellular matrix (ortholog) AND  
INTERACTS WITH (S)-colchicine AND  1 2 4-










ENCODES a protein that exhibits actin monomer binding 
(inferred) AND  INVOLVED IN actin cytoskeleton 
organization (inferred) AND  sequestering of actin 
monomers (inferred) AND  spermatid development 








cytoskeleton (inferred) AND  INTERACTS WITH 
17alpha-ethynylestradiol AND  2 3 7 8-











INVOLVED IN cell adhesion (ortholog) AND  cell death 
(ortholog) AND  positive regulation of axon extension 
(ortholog) AND  PARTICIPATES IN cytokine mediated 
signaling pathway AND  FOUND IN cell surface 
(ortholog) AND  plasma membrane (ortholog) AND  
ruffle (ortholog) AND  INTERACTS WITH 1 3-
dinitrobenzene AND  2 3 7 8-tetrachlorodibenzodioxine 









ENCODES a protein that exhibits identical protein 
binding (ortholog) AND  PARTICIPATES IN cell cycle 
pathway  mitotic AND  INTERACTS WITH cefaloridine 














FOUND IN integral to membrane (inferred) AND  
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